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Protein phosphorylation, the reversible, covalent addition of phos-
phate groups to serine, threonine or tyrosine residues, is a rapid and
efﬁcient mechanism for modulating protein function. This post-r protein 1; BBB, blood-brain barrier;
E, experimental autoimmune enceph
, interleukin; IRF, interferon-regula
itogen-activated protein kinase; MK
f activated B cells;NFT, neuroﬁbrillar
osphatase 2A; PRR, pattern recognitio
nding protein; TAK1, transforming gr
-like receptor; TNF, tumor necrosis f
ptor domain-containing adaptor indutranslational odiﬁcation alters the charge, local shape and global confor-
mation of substrate proteins, inﬂuencing their interactions with other
molecules, and modulating their subcellular localization, stability or
function. The human genome encodes more than 500 kinases that cata-
lyze protein phosphorylation, and fewer than 200 protein phosphatasesCCR4/NOT, carbon catabolite repressor 4/never on TATA-less; CIP2A, cancerous inhibitor of
alopathy; HEAT, Huntingtin - Elongation factor - A subunit of PP2A - Target of rapamycin
tory factor; JNK, cJun N-terminal kinase; LCMT-1, leucine carboxymethyl transferase 1;
2, MAPK-activated kinase 2; MKK, MAPK kinase; MS, multiple sclerosis; MyD88, myeloid
y tangles; PAD, PP2A-activating drug; PAMP, pathogen-associatedmolecular pattern; PME-
n receptor; ROS, reactive oxygen species; S1P, sphingosine-1-phosphate; S1PR, S1P recep-
owth factorβ-activated kinase; TGFβ, transforming growth factorβ; TIRAP, Toll/interleukin
actor; TRAF, TNF receptor interacting factor; TRAM, Toll/interleukin 1 receptor domain-
cing interferon β; TTP, tristetraprolin; UVB, ultraviolet B.
Fig. 1. Composition of the PP2A holoenzyme. Systematic names are indicated for
scaffolding (A), regulatory (B) and catalytic (C) protein subunits. Alternative names are
indicated in Table 1.
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leading. In some cases substrate speciﬁcity can be conferred by regula-
tory subunits distinct from the proteins that possess catalytic activity.
Duplication and evolutionary diversiﬁcation of regulatory subunits can
therefore greatly expand the functional roles of kinases or phosphatases
without a parallel increase in the number of kinase- and phosphatase-
encoding genes. Such diversiﬁcation appears to have been particularly
important in the evolution of protein phosphatase(s) 2A (PP2A), the
subject of this review.
Since protein phosphorylation has profound effects on every aspect
of cell biology, precise balance between the activities of kinases and
phosphatases is required for the proper regulation of cell function. Strik-
ingly, such balance is not seen in scientiﬁc literature, where published
articles with “kinase” outnumber those with “phosphatase” in their
titles by a factor of almost ten to one. There are several possible explana-
tions for such bias. By deﬁnition phosphorylation is an energy-
dependent process requiring the consumption of ATP. For reasons of
energy economy, evolution may have favored use of protein phosphor-
ylation as a means of response to perturbation, and dephosphorylation
as a means of restoring or maintaining equilibrium. This generalization
seems broadly true, although many readers will readily think of excep-
tions. In this perspective, phosphatase activity may be seen as rather
non-speciﬁc, unregulated, and consequently not very interesting as a
subject of study. Recent advances suggest that these are all misconcep-
tions. Inhibition of kinases to prevent harmful cell activation is more
conceptually and practically straightforward than stimulation of phos-
phatases to promote restoration of homeostasis. Much like the scientiﬁc
literature, patent literature demonstrates strong bias towards targeting
of kinases rather than phosphatases. In this review we argue that im-
proved understanding of cell signallingmay open up new opportunities
to exert therapeutic effects via activation of the phosphatase(s) PP2A.Table 1
Systematic and alternative names of PP2A protein subunits. Based onHumanGenomeOr-
ganization Gene Nomenclature Committee and Genecards (https://www.genecards.org).
Asterisks indicatewhere different protein products are known to be generated via alterna-
tive splicing of primary transcripts.
Subunit type Sub-type Systematic name Alternative names
A (scaffolding) PPP2R1A PR65α, PR65A, PP2A-Aα, MRD36
PPP2R1B PR65β, PR65B, PP2A-Aβ
B (regulatory) B PPP2R2A Bα, PR55α, B55α
PPP2R2B* Bβ, PR55β, B55β, SCA12
PPP2R2C Bγ, PR55γ, B55γ
PPP2R2D Bδ, PR55δ, B55δ, KIAA1541
B” PPP2R3A* B”α, PR130, PR72
PPP2R3B* B”β, PR70, PR48
PPP2R3C B”γ, C14orf10, G5PR
B’ PPP2R5A B’α, PR61α, B56A, B56α
PPP2R5B B’β, PR61β, B56B, B56β
PPP2R5C* B’γ, PR61γ, B56G, B56γ
PPP2R5D* B’δ, PR61δ, B56D, B56δ, MRD35
PPP2R5E* B’ε, PR61ε, B56E, B56ε
B”’Striatin STRN B”’α, PPP2R6A, PR93, STRN1
STRN3 B”’β, PPP2R6B, PR110, SG2NA
STRN4 B”’γ, PPP2R6C, zinedin, ZIN
C (catalytic) PPP2CA PP2A-Cα, PP2CA, PP2Aα
PPP2CB PP2A-Cβ, PP2CB, PP2Aβ2. The regulation of PP2A function
2.1. PP2A subunits and regulators
Readers may have noticed our reference to “the phosphatase
(s) PP2A”. The reason for this form of words is that PP2A is not a single
entity but a family of heterotrimeric holoenzymes. The active enzyme is
a complex containing a 65 kD scaffolding subunit (A), a 36 kD catalytic
subunit (C) and a speciﬁcity-determining subunit of variable size
(B) (Haesen, Sents, Lemaire, Hoorne, & Janssens, 2014; Lambrecht,
Haesen, Sents, Ivanova, & Janssens, 2013). Two distinct and functionally
non-redundant genes, PPP2R1A and PPP2R1B, encodeα and β scaffold-
ing subunits of PP2A. These proteins contain ﬁfteen repeats of a 39
amino acid structural motif known as the HEAT domain, being present
in Huntingtin, Elongation factor, the A subunit of PP2A, and Target of
Rapamycin. The HEAT domains stack one above another to form an ex-
tended hook structure, with somewhat ﬂexible loops between them,
and a highly ﬂexible hinge between the twelfth and thirteenth repeats
(Cho & Xu, 2007; Jiang et al., 2013; Y. Xu et al., 2006). There are also
two distinct genes, PPP2CA and PPP2CB, encodingα andβ catalytic sub-
units. In the majority of adult tissues the α isoforms of both scaffolding
and catalytic subunits appear to be predominant. Functional complexity
and diversity of PP2A therefore arise largely via the B subunits, which
determine both the subcellular localization and substrate speciﬁcity of
individual heterotrimers (Haesen et al., 2014; Lambrecht et al., 2013).
B subunits are encoded by four families of genes, comprising a total of
ﬁfteen genes. These are the B (PPP2R2) family, with four members;
the B’ (PPP2R5) family, with ﬁve members; the B” (PPP2R3) family,
with three members; and the Striatin (STRN) family, with three mem-
bers (Fig. 1). Several of these genes generate different products via alter-
native splicing. The four families of proteins are structurally distinct
from one another, and their accommodation within the holoenzyme is
permitted by the intrinsic ﬂexibility of the A (scaffolding) subunit. Inthis reviewwewill adhere to the systematic names for B subunits. Alter-
native names are listed in Table 1.
PP2A profoundly inﬂuences all aspects of cell biology, therefore its
function is tightly regulated at several levels. As reviewed extensively
elsewhere (Janssens, Longin, & Goris, 2008; Sents, Ivanova, Lambrecht,
Haesen, & Janssens, 2013), assembly of holoenzymes is strictly con-
trolled to prevent the formation of catalytically active complexes lack-
ing correct substrate speciﬁcity. Unpartnered catalytic subunits are
subject to ubiquitination and proteasomal degradation. The protein α4
(otherwise known as Immunoglobulin Binding Protein 1 or IGBP1)
both stabilizes and inactivates free C subunits, thereby regulating their
availability for assembly into holoenzymes (Kong, Ditsworth, Lindsten,
& Thompson, 2009). The ATP-dependent chaperone phosphotyrosyl
phosphatase activator (encoded by PPP2R4) is required for correct fold-
ing of the catalytic subunit and incorporation of manganese ions at the
catalytic site (Cho & Xu, 2007; Guo et al., 2014; Jordens et al., 2006).
The catalytic subunit is also post-translationally modiﬁed by methyla-
tion of the free carboxyl group of the C-terminal leucine residue,
Leu309. This unusual modiﬁcation is performed by leucine
carboxymethyl transferase 1 (LCMT-1), and can be reversed by protein
phosphatase methylesterase 1 (PME-1). Assembly of certain holoen-
zyme complexes, particularly those containing B subunits of the
PPP2R2 family, is critically dependent on methylation of the C subunit
(Cho & Xu, 2007). It has been reported that phosphorylation of the ad-
jacent tyrosine residue Tyr307 antagonizes Leu 309 methylation, ren-
dering PP2A subject to control by protein tyrosine kinases and
phosphatases (Chen, Martin, & Brautigan, 1992; Chen, Parsons, &
Brautigan, 1994; Liu et al., 2008; Zonta et al., 2015). However, Tyr307
phosphorylation is not supported by unbiased phospho-proteomic
studies (Hornbeck et al., 2015) and an antibody commonly used to de-
tect this modiﬁcation is unreliable (Ogris, Sontag, Wadzinski, & Narla,
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phosphatases therefore require clariﬁcation.
Protein kinase A-mediated phosphorylation of the B subunit
PPP2R5D increases the activity of PP2A against certain phosphoprotein
substrates (Ahn et al., 2007; Dodge-Kafka et al., 2010; Ranieri, Kemp,
Burgoyne, & Avkiran, 2018; Yu & Ahn, 2010). According to a database
of unbiased, high throughput proteomic studies (Hornbeck et al.,
2015), othermembers of the PPP2R5 family also appear to bephosphor-
ylated within similar, highly charged N-terminal domains, suggesting
that they too may be regulated via phosphorylation by cyclic AMP-
dependent (or other) kinases. Perusal of the same database indicates
many other well-documented but unstudied post-translational modiﬁ-
cations of B subunits. For example, members of the STRN family appear
to be extensively phosphorylated. There is also consistent evidence for
the acetylation of both PPP2R2A and PPP2R2D at lysine residues near
to their C-termini. At least in the plant Arabidopsis thaliana, PP2A associ-
ates with protein acetylases and deacetylases in the vicinity of microtu-
bules, where it may participate in the control of cytoskeletal dynamics
(Tran et al., 2012). Although some studies have hinted at crosstalk be-
tween phosphorylation and acetylation of PP2A substrates
(Nunbhakdi-Craig et al., 2007), consequences of acetylation of PP2A
subunits have not been investigated as far as we know.
The cellular repertoire of PP2A targets is governed by the expression
of B subunits, which is under developmental and tissue-speciﬁc control
(Haesen et al., 2014; Reynhout & Janssens, 2019). In the transformed T
cell line Jurkat, engagement of the T cell receptor caused up-regulation
of PPP2R5CmRNA and the corresponding protein (Breuer et al., 2014).
PPP2R2AmRNA and its protein productwere up-regulated by interferon
treatment of primary human macrophages (Schott et al., 2018). Our
own, unpublished observations revealed both increases and decreases
in expression of various B subunits mRNAs after lipopolysaccharide
(LPS) stimulation of primary human and mouse macrophages. We
hypothesise that such changes result in stimulus-dependent modula-
tion of PP2A activity and/or substrate speciﬁcity. However, the role of
regulated B subunit expression in signal transduction has not been ex-
tensively studied.
Several endogenous proteins have been shown to negatively regu-
late PP2A function. Both PME-1 and α4 could be considered as PP2A in-
hibitors, although this does not do justice to their complex and essential
roles in assembly of the holoenzyme. The best characterized inhibitors
are ANP32A (Acidic Nuclear Phosphoprotein 32A, otherwise known as
PP2A inhibitor 1); the closely related protein ANP32E; SET (also
known as PP2A inhibitor 2); and CIP2A (cancerous inhibitor of PP2A).
SET binds to PPP2CA and inhibits its phosphatase activity (Arnaud
et al., 2011). In contrast, CIP2A inhibits holoenzyme activity by binding
to PPP2R5A or PPP2R5C components (Wang et al., 2017), its speciﬁcity
for other B subunits remaining unclear. Thus the interaction of inhibitor
proteins with PP2A provides a level at which phosphatase activity can
be further controlled by cellular signaling pathways.
2.2. Sphingolipid metabolism and the control of PP2A function
Sphingolipids are pleiotropic lipid secondmessengers, whichmodu-
late cellular functions by several mechanisms (Aoki, Aoki, Ramanathan,
Hait, & Takabe, 2016; Kunkel, Maceyka, Milstien, & Spiegel, 2013; Oaks
& Ogretmen, 2014; Spiegel & Milstien, 2011). The polar, membrane as-
sociated sphingolipid sphingomyelin is cleaved by sphingomyelinases,
releasing phosphocholine and ceramide (Fig. 2). Ceramide causes acti-
vation of PP2A (Chalfant, Szulc, Roddy, Bielawska, & Hannun, 2004;
Cornell et al., 2009; Dobrowsky, Kamibayashi, Mumby, & Hannun,
1993; He, Du, Ke, Wen, & Zhang, 2019; Mukhopadhyay et al., 2009;
Ruvolo, Deng, Ito, Carr, &May, 1999), an effect that is attributed to bind-
ing of the lipid to SET, and disruption of the inhibitory SET-PPP2CA in-
teraction (Mukhopadhyay et al., 2009; Saddoughi et al., 2013). Furtherprocessing of ceramide has additional cell signaling consequences,
which will be brieﬂy discussed here because of their relevance to
PP2A as a therapeutic target. Ceramidase enzymes cleave the acyl side
chain from ceramide to yield sphingosine. This lipid is phosphorylated
by sphingosine kinases 1 or 2 (Sphk1 and Sphk2) to generate
sphingosine-1-phosphate (S1P), a lipid messenger with multiple, com-
plex and context-dependent effects on the immune system (reviewed
in Aoki et al., 2016; Kunkel et al., 2013; Maceyka, Harikumar, Milstien,
& Spiegel, 2012; Spiegel & Milstien, 2011; Strub, Maceyka, Hait,
Milstien, & Spiegel, 2010). Within the cell, S1P functions as a cofactor
for TRAF2 (TNF receptor associated factor 2), an E3 ubiquitin ligase
that plays an essential role in signaling from the TNF receptor to the
transcription factor NF-κB (nuclear factor κ light chain enhancer of acti-
vated B cells) (Alvarez et al., 2010; Park et al., 2015; Spiegel & Milstien,
2011) (see below). It may also function in a similar fashion to facilitate
Toll-like receptor signaling by enhancing the E3 ubiquitin ligase activity
of TRAF6 (Spiegel & Milstien, 2011). Sustained activation of NF-κB by
S1P contributes to enhanced expression of pro-inﬂammatory and pro-
survival genes in the context of colitis-associated cancer (Liang et al.,
2013). Other intracellular effects of S1P have been reported, including
the inhibition of histone deacetylases 1 and 2 in the nucleus, overcom-
ing the suppression of transcription by these epigenetic regulators
(Ebenezer, Fu, Suryadevara, Zhao, & Natarajan, 2017; Hait et al., 2009;
Yan et al., 2018). The gene speciﬁcity of transcriptional regulation by
this mechanism is not fully understood.
The most well studied actions of S1P follow its export from the cell,
principally by the transporter Spinster 2. Thereafter, S1P acts as an ex-
tracellular ligand for its receptors, S1PR1-5, in a process known as
inside-out signaling. The ﬁve S1P receptors belong to the superfamily
of G protein coupled receptors. The nature of the signal transduced by
each S1P receptor is determined by the GTPase complexes with which
it is associated at the cell membrane. This ﬂexibility allows S1P to
exert cell type- and context-speciﬁc effects. The engagement of S1PR2
or 3 on vascular endothelial cells promotes activation of NF-κB via cou-
pling to Gα12/13, the small GTPase protein RhoA and RhoA-activated ki-
nase (Fernandez-Pisonero et al., 2012; Keul et al., 2011; Sanchez et al.,
2007; Skoura et al., 2007; Zhang, Yang, et al., 2013; Zhang, An et al.,
2013). This mechanism increases expression of adhesion molecules
and inﬂammatorymediators, whilst impairing endothelial barrier func-
tion. In contrast the engagement of S1PR1 on vascular endothelial cells
contributes to the maintenance of barrier function.
Another very important role of S1P-S1PR signaling is in the regula-
tion of leukocyte trafﬁc (Aoki et al., 2016; Spiegel & Milstien, 2011).
Egress of leukocytes from lymphoid tissues is driven by an S1P gradient
between lymphoid tissue, where concentration is low, to circulating
blood or lymph, where high S1P concentrations are maintained by dis-
tinctmechanisms. The length of residency of leukocytes in lymphoid or-
gans is regulated in part by adjusting the cell surface expression of the
receptor S1PR1,making themmore or less sensitive to the S1P gradient.
The S1P analogue FTY720 (otherwise known as Fingolimod or Gilenya)
is licensed for use inmultiple sclerosis (MS), an auto-immune disease in
which demyelination of neurons causes impairment of function, with
consequent physical, cognitive and psychiatric symptoms (Brinkmann
et al., 2010; Chaudhry, Cohen, & Conway, 2017; Mehling, Kappos, &
Derfuss, 2011). FTY720 is phosphorylated by Sphk2 (Kharel et al.,
2005; Paugh, Payne, Barbour, Milstien, & Spiegel, 2003; Zemann et al.,
2006), and the product of this reaction causes internalization and
proteasome-mediated degradation of S1P receptors (Graler & Goetzl,
2004; Mullershausen et al., 2009; Oo et al., 2007; Sykes et al., 2014).
The consequent impairment of egress of lymphocytes from lymphoid
tissues is thought to underlie therapeutic effects of FTY720 in MS
(Brinkmann et al., 2010).
However, the effects of FTY720 are considerably more complex
(Pitman,Woodcock, Lopez, & Pitson, 2012). FTY720-P initially functions
Fig. 2. Sphingolipid metabolism. Representative structures of lipid compounds are illustrated. For comparison, structures of FTY-720 and phospho-FTY-720 are also shown.
184 A.R. Clark, M. Ohlmeyer / Pharmacology & Therapeutics 201 (2019) 181–201as a potent agonist of S1P receptors, in particular S1PR1 (Brinkmann
et al., 2002). Even when this receptor is internalized, it may continue
to generate signals that inﬂuence cell behavior (Mullershausen et al.,
2009). Consequently, there is often ambiguity as to whether effects
of FTY720 in vivo are mediated by agonistic or antagonistic effects
on S1P receptors. More relevant here, being structurally related to cer-
amide (Fig. 2), FTY720 also binds to SET, interrupting the interaction
of the inhibitor with PP2A and promoting PP2A activation (Liu et al.,
2008; Matsuoka, Nagahara, Ikekita, & Shinomiya, 2003; Neviani
et al., 2007; Neviani et al., 2013; Pippa et al., 2014; Roberts et al.,
2010; Saddoughi et al., 2013; Yang, Huang, Lu, Li, & Huang, 2012).
Throughout this review, we will return to this intriguing drug and
its derivatives, their mechanisms of action and actual or potential clin-
ical uses.3. PP2A and cancer
3.1. Dysregulation of PP2A in cancer
As reviewed in depth elsewhere, impairment of PP2A function is a
very common feature of many cancers, therefore PP2A may be consid-
ered as a tumor suppressor (Carratu, Signorile, De Rasmo, Reale, &
Vacca, 2016; Grech et al., 2016; Haesen et al., 2014; Janssens &
Rebollo, 2012; O'Connor, Perl, Leonard, Sangodkar, & Narla, 2017;
Ruvolo, 2016; Westermarck & Hahn, 2008). Dysregulated phosphoryla-
tion and function of PP2A substrates contributes to several hallmarks of
cancer (Hanahan & Weinberg, 2011), including inﬂammation as
discussed in detail below. In cancer, many different routes to functional
impairment of PP2A have been described, reﬂecting the magnitude of
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tastasis. (1) Okadaic acid, calyculin A and microcystin-LR are toxins de-
rived from aquatic microorganisms, which exert tumor-promoting
effects by directly inhibiting PP2A (Fujiki & Suganuma, 2009). These
and related compounds can be useful for investigating functions of
PP2A, although their effects must be interpreted with caution because
of their imperfect speciﬁcity for PP2A (Swingle, Ni, & Honkanen,
2007). (2) Small and middle T antigens of DNA tumor viruses also di-
rectly inhibit PP2A function, promoting proliferation of infected cells
and conferring a replicative advantage to the virus (Chen et al., 2007;
Cho et al., 2007; Guergnon et al., 2011; Sablina & Hahn, 2008).
(3) Oncogenically dysregulated tyrosine kinases impair PP2A function
(Chen et al., 1994; Zonta et al., 2015), although the precise mechanism
remains uncertain as noted above. (4) Expression of speciﬁc B subunits
is decreased through chromosomal deletion, epigenetic or micro-RNA-
mediated silencing (Ruvolo, 2015). (5) Somatic mutations within the
scaffolding subunit PPP2R1A speciﬁcally inﬂuence recruitment of par-
ticular B subunits (Haesen et al., 2016; Ruediger, Ruiz, & Walter,
2011). (6) Expression of negative regulators such as CIP2A and SET/is el-
evated (Hung & Chen, 2017; Kauko & Westermarck, 2018; Sooﬁyani,
Hejazi, & Baradaran, 2017). (7) Expression of positive regulators such
as PPP2R4 is decreased (Sents et al., 2017). For additional references
see the review articles mentioned at the start of this paragraph.
3.2. Therapeutic targeting of PP2A in cancer
As reviewed extensively elsewhere (Carratu et al., 2016; Grech et al.,
2016; Lambrecht et al., 2013; O'Connor et al., 2017; Perrotti & Neviani,
2013), PP2A-activating drugs (PADs) are being sought and developed
by cancer researchers in academia and the pharmaceutical industry.
One approach is based on the observation that the licensed drug
FTY720 binds to the endogenous inhibitor protein SET, causing dere-
pression of PP2A activity (Liu, Zhao, et al., 2008; Matsuoka et al., 2003;
Neviani et al., 2007; Neviani et al., 2013; Pippa et al., 2014; Roberts
et al., 2010; Saddoughi et al., 2013; Yang et al., 2012). This suggested
that the immunomodulatory drug might be repurposed as an anti-
tumor agent (Enjeti, D'Crus, Melville, Verrills, & Rowlings, 2016;
Patmanathan, Yap, Murray, & Paterson, 2015; Rincon et al., 2015).
FTY720 itself displayed promising effects in several pre-clinical cancer
models (Baldacchino et al., 2014; Cristobal et al., 2014; Cristobal et al.,
2016; Garner et al., 2018; Neviani et al., 2007; Oaks et al., 2013;
Ramaswamy, Spitzer, & Kentsis, 2015; Szymiczek et al., 2017;
Velmurugan et al., 2018; Wallington-Beddoe et al., 2012; Wallington-
Beddoe, Hewson, Bradstock, & Bendall, 2011; Zonta et al., 2015). In
some cases it overcame resistance to kinase inhibitors and chemothera-
peutics that are commonly used as ﬁrst line cancer treatments (Kiyota
et al., 2013; McDermott et al., 2014; Neviani et al., 2013; Perrotti &
Neviani, 2006; Rincon et al., 2015; Smith et al., 2016), indicating that
combination therapies incorporating FTY720 or other PADs may be
highly promising (Mazhar, Taylor, Sangodkar, & Narla, 2019).
Anti-tumor actions of FTY720 do not require its phosphorylation. In
fact, lymphopenia and immuno-suppression driven by antagonism of
S1P receptors are considered to be potential obstacles to the use of
FTY720 in cancer. Therefore, some researchers have sought to identify
FTY720 derivatives that cannot be phosphorylated, yet retain anti-
tumor effects independent of the S1P-S1PR axis (Toop et al., 2016).
FTY720 derivatives known as AAL(s) and OSU-2S were generated by
substitution of the phosphorylatable pro-R hydroxyl group (Kiuchi
et al., 1998; Omar et al., 2011) (Fig. 3A). These molecules cannot be
phosphorylated or bind to S1PRs, but retain the SET-binding, PP2A-
activating and anti-tumor properties of their parent (Mani et al., 2015;
Mani et al., 2017; Omar et al., 2011; Omar, Tolba, Hung, & Al-Tel, 2016;
Roberts et al., 2010; Smith et al., 2016). Replacement of the saturated li-
pophilic chain may also be possible while retaining PP2A-activating
properties, as for example in P053 (Turner et al., 2018) (Fig. 3A). Edinger
and colleagues have developed aza-cyclic FTY720 analogs that are againnot phosphorylated but retain SET-binding and PP2A-activating proper-
ties (for example SH-BC-893; Fig 3A) (Kim et al., 2016; Kubiniok et al.,
2019; McCracken et al., 2017). They are claimed to have reduced
cardio-vascular and other known off-target effects of FTY-720 (Chen
et al., 2016; Perryman et al., 2016). A third line of medicinal chemistry
led to SET-binding compounds exempliﬁed by MP07-66 (Tibaldi et al.,
2017; Zonta et al., 2015) (Fig. 3A). Although these compounds generally
retain the amphiphilic, sphingolipid-like structure of FTY-720, no as-
sumptions can bemade about their off-target effects and safety proﬁles,
and little information is yet available. Apolipoprotein E-derivedpeptides
such as COG1410 also bound to SET, activated PP2A (Christensen et al.,
2011) and exerted anti-tumor effects in several experimental models
of cancer (Agarwal et al., 2014; Christensen et al., 2011; Fujiwara et al.,
2013; Hu et al., 2015; Richard et al., 2016; Shlomai et al., 2017; Switzer
et al., 2011). The precise mechanism of action and pathway to transla-
tion of these peptides are unclear. The utility of all of these diverse
SET-bindingmolecules depends upon how strongly PP2A activity is reg-
ulated by SET in the relevant cellular context.
The biguanidine compound metformin (Fig. 3B), widely used as an
anti-diabetic drug, was reported to interrupt the interaction between
the catalytic subunit PPP2CA, the regulator of PP2A holoenzyme assem-
bly IGBP1, and the ubiquitin E3 ligase Midline 1 (Demir, Koehler,
Schneider, Schweiger, & Klocker, 2014; Kawashima & Kirito, 2016;
Kickstein et al., 2010; Zhang et al., 2019). It is thought that metformin
releases PP2CA and IGBP1 from an inhibitory effect of Midline 1, pro-
moting the assembly of functional PP2A holoenzyme complexes. Fur-
ther work is required to clarify the mechanism of action of metformin
on PP2A, and the extent to which this contributes to anti-
inﬂammatory effects of metformin (Saisho, 2015).
Other PP2Aactivating compounds interact directlywith components
of the PP2A holoenzyme. Anti-psychotic phenothiazine drugs such as
chlorpromazine (Fig. 3C) have anti-proliferative effects, but could not
beused to treat cancer because of harmful side-effects related to engage-
ment of G protein-coupled receptors (GPCRs) and amine transporters. A
key mechanistic ﬁnding was that phenothiazines promoted PP2A-
mediated nuclear localization of the forkhead box transcription factor
FOXO1, leading to inhibition of cell division (Gutierrez et al., 2014; Kau
et al., 2003;Yanet al., 2008). Inparallel itwasdiscovered that effectsme-
diated by GPCRs and amine transporters could be eliminated while
retaining PP2A-mediated anti-proliferative properties (Kastrinsky
et al., 2015). This led to tricyclic sulfonamide compounds such as DBK-
1154 (Fig. 3C), which bind in the HEAT repeats of the PP2A scaffold pro-
teinPPP2R1Aat a site proximal to theC-terminal of the catalytic subunit,
eliciting robust PP2A activation and impairing growth of non small cell
lung cancer, prostate and pancreatic cancers (Allen-Petersen et al.,
2019; Kauko et al., 2018; McClinch et al., 2018; Sangodkar et al., 2017;
Tohme et al., 2019). In vitro, anti-proliferative effects on non small cell
lung cancer cells were accompanied by extensive changes to the
phospho-proteome, consistent with PP2A-mediated inactivation of
pathways that promote cell cycle progression (Wiredja et al., 2017).
Grossman and colleagues have reported that the complex plant-
derived lactone withaferin A (Fig. 3D) alkylates a speciﬁc cysteine resi-
due of PPP2R1A and elicits an irreversible PP2A activating effect
(Grossman et al., 2017). Further medicinal chemistry development led
to a series of simpler, synthetic molecules that promoted alkylation of
the same PPP2R1A cysteine residue. These are exempliﬁed by DKM 2-
90 and JNK 1-40 (Fig. 3D). Compounds that directly target PP2A might
be expected tohavebroader activity than thosewhich target onespeciﬁc
PP2A inhibitor. It remains to be seenwhether this translates to a clinical
advantage,whether reversible or irreversible PP2A activation is prefera-
ble, or whether alkylating agents have utility outside of cancer therapy.
Various other molecules have been reported to activate PP2A with
potentially therapeutic effect. Amongst these are salmeterol, formoterol
and salbutamol (Fig. 3E), agonists of β-adrenergic receptors that are
commonly used in the treatment of asthma (Bastan, Eskandari,
Ardakani, & Peachell, 2017; Hatchwell et al., 2014; Kobayashi,
Fig. 3. Therapeutic targeting of PP2A. Various compounds reported to activate PP2A are shown, with licensed drugs boxed. A) FTY720 and derived compounds; B)Metformin; C) the anti-
psychotic phenothiazine chlorpromazine and daughter compound DBK-1154; D) compounds reported to promote alkylation of PPP2CA; E) β-adrenergic receptor agonists; F) caffeine-
related compounds theophylline and EHT, and the PME-1 inhibitor compound 28.
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ophylline (Fig. 3F), a methylxanythine drug closely related to caffeine,
and used to treat asthma and chronic obstructive pulmonary disease
(Patel et al., 2016); and eicosanoyl-5-hydroxytryptamide (EHT;
Fig. 3F), a related compound that was discovered in coffee and is now
marketed as a nutraceutical product (K. W. Lee, Im et al., 2013). EHT
may inﬂuence PP2A activity by modulating the methylation state of
the C-terminal leucine residue. Other researchers have sought to opti-
mize speciﬁc inhibitors of the demethylase enzyme PME-1
(Bachovchin et al., 2011; Zuhl et al., 2012), leading to the discovery of
sulfonyl acrylonitriles exempliﬁed by Compound 28 (Fig. 3F). These
compounds are described as experimental tools, yet may have some
anti-cancer applications (Kaur & Westermarck, 2016; Pusey et al.,
2016).
As highlighted in Fig. 3,molecules of several distinct chemical classes
have been shown to activate PP2A in different ways, targeting the PP2Aholoenzyme itself or its regulators by reversible and irreversible mech-
anisms. Differences of composition and mechanism of action are very
likely to result in differences of both on- and off-target cellular effects,
context-dependent efﬁcacy, toxicity and tolerability. It isworth pointing
out that several licensed drugswithwell-known and broadly acceptable
safety proﬁles have been reported to activate PP2A by direct, indirect or
as yet unknownmechanisms. Arguably this increases the likelihood that
drugs which are actually designed to activate PP2A will be tolerated.
4. Involvement of PP2A in the control of inﬂammation
4.1. Introduction
The interactions between pathogen-associated molecular patterns
(PAMPs) and their cognate pattern recognition receptors (PRRs) are
the bedrock of innate immunity and inﬂammation (O'Neill,
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be identiﬁed, is expressed on the surface of many cell types, but most
notably monocytes, macrophages and dendritic cells. With the assis-
tance of accessory proteins, TLR4 recognizes LPS, an essential compo-
nent of the cell wall of gram negative bacteria. Upon binding of LPS,
TLR4 triggers a signaling cascade that promotes expression of cytokines,
chemokines, other inﬂammatory mediators and microbicidal gene
products (Arthur & Ley, 2013; O'Neill et al., 2013). PAMPs recognized
by other PRRs are commonly structural components of pathogens, or
forms of nucleic acid that are associated with pathogens. These are
interpreted by the cell as generic evidence of the presence of microbes,
and all are capable of triggering inﬂammatory responses. There are subtle
differences in the signaling pathways engaged and the programmes of
gene expression activated, allowing cells to tailor their responses to the
nature of the challenge. Pro-inﬂammatory cytokines such as interleukin
1β (IL-1β) and tumor necrosis factorα (TNFα) bind to their own cell sur-
face receptors, and the initial stages of their signaling pathways differ
from those of the PRRs. However, common signaling components are en-
gaged downstream, and overlapping phosphorylation-dependentmech-
anisms are deployed to bring about changes of cellular function. Herewe
focus on three signaling pathways in which there is strong evidence for
involvement of PP2A (Fig. 4).
4.2. NF-κB (nuclear factor κ light chain enhancer of activated B cells)
The binding of LPS to TLR4 induces a conformational change in the
intracellular domain of the receptor, which drives the assembly of aFig. 4. Sites of action of PP2A in Toll-like receptor 4- (TLR4-)mediated signaling. TLR4 regulates
phosphorylation-mediated signaling cascades, which are shown here in cartoon form. Signals v
simplicity is not indicated here. Black symbols represent protein dephosphorylation by PP2A. G
IκBα, α inhibitor of NF-κB; IKK, IκBα kinase; IRF, interferon-regulatory factor; JNK, cJun N-term
protein kinase; MK2, MAPK-activated kinase 2; MKK, MAPK kinase; MyD88, myeloid different
protein; TAK1, transforming growth factor β-activated kinase; TIRAP, Toll/interleukin 1 rec
interacting factor; TRAM, Toll/interleukin 1 receptor domain-containing adaptor molecule; T
tristetraprolin.very high molecular weight signaling complex, culminating in the re-
cruitment and activation of tumor necrosis factor associated factor
(TRAF6; Fig. 4). TRAF6 is an E3 ubiquitin ligase, which catalyses the for-
mation of long chains of covalently linked ubiquitin peptides attached
either to TRAF6 itself or to other components of the signaling complex.
First, an isopeptide bond is created between the C-terminal glycine res-
idue of a single, 76 amino acid ubiquitin polypeptide and a lysine resi-
due of the acceptor protein. Then the chain is extended by sequential
addition of several more ubiquitin polypeptides, each forming an
isopeptide bond to lysine 63 of the preceding ubiquitin moiety. In
other words these ubiquitin chains are “K63-linked”. Chains created
by the linear ubiquitin assembly complex (LUBAC) are also increasingly
recognized as important contributors to inﬂammatory responses
(Shimizu, Taraborrelli, & Walczak, 2015). In either case, poly-ubiquitin
chains create scaffolds for recruitment and activation of other signaling
molecules, which will ultimately convert the TLR4 signal into
transcriptionally- and post-transcriptionally-mediated changes in the
expression of inﬂammatory and antimicrobial genes. One of the most
important mediators of this response is the transcription factor NF-κB
(Taniguchi & Karin, 2018). In resting cells, NF-κB is cytoplasmically se-
questered in an inactive form throughmasking of its nuclear localisation
signal by IκBα (inhibitor of NF-κB α). The activation of NF-κB requires
degradation of IκBα, which is accomplished as follows. Transforming
growth factor β (TGFβ)-associated kinase 1 (TAK-1) is recruited to the
TLR4 signaling complex via ubiquitin binding domains of the associated
TAK-1-bindingproteins 2 or 3 (TAB-2/3). The IκBa kinase (IKK) complex
is recruited via a ubiquitin-binding domain of the scaffold protein IKKγ.gene expression via the assembly of large signaling complexes and the activation of various
ia TRAM and TRIF to IRF3 originate from an endosomal compartment, which for reasons of
rey circles represent linear or K63-linked poly-ubiquitin chains. AP-1, activator protein 1;
inal kinase; LUBAC, linear ubiquitin chain assembly complex; MAPK, mitogen-activated
iation factor 88; NF-κB, nuclear factor κ enhancer of activated B cells; TAB, TAK1 binding
eptor domain-containing adaptor protein; TLR, Toll-like receptor; TRAF, TNF receptor
RIF, Toll/interleukin 1 receptor domain-containing adaptor inducing interferon β; TTP,
188 A.R. Clark, M. Ohlmeyer / Pharmacology & Therapeutics 201 (2019) 181–201TAK-1 molecules, brought into proximity via clustering at the poly-
ubiquitin scaffold, activate one another via phosphorylation of threo-
nines 184 and 187. They then activate IKKβ via phosphorylation of
serines 177 and 181. Once activated, IKKβ phosphorylates IκBα at ser-
ines 32 and 36. These phosphorylations promote poly-ubiquitination
of IκBα with K48 linkages (ie each new ubiquitin molecule is ligated
to lysine 48 of the preceding molecule). Unlike the K63 chain, this
post-translational modiﬁcation is recognized as a signal for protein deg-
radation by the proteasome. As a consequence of IκBα degradation, NF-
κB is released from its repressive complex and allowed tomigrate to the
nucleus, where it activates transcription of large numbers of pro-
inﬂammatory, anti-microbial and anti-apoptotic genes. The process is
further modulated by additional phosphorylation events (Christian,
Smith, & Carmody, 2016; Huang, Yang, Lamb, & Chen, 2010; Neumann
&Naumann, 2007). RelA (reticuloendotheliosis viral oncogene homolog
A), a component of the canonical NF-κB dimer, is phosphorylated by
IKKβ at Ser536, a modiﬁcation associated with transcriptional activa-
tion. A variety of other kinases have been reported to modulate tran-
scription via the phosphorylation of RelA or other NF-κB components
(Christian et al., 2016; Huang et al., 2010; Neumann&Naumann, 2007).
The NF-κB signaling pathway depends on serine-threonine phos-
phorylation at several points, suggesting that it may be regulated by
serine-threonine phosphatases. Okadaic acid, calyculin A and
microcystin-LR are all reported to promote nuclear localization, phos-
phorylation and transcriptional activation of NF-κB in a wide variety
of cell types (Feng, Ohmori, & Chang, 2006; Grossman, Shanley,
Denenberg, Zhao, & Wong, 2002; Miskolci et al., 2003; Ozaki et al.,
2006; Tanaka et al., 2007; Thevenin et al., 1990; Zhang et al., 2012). In
many cases the PP2A inhibitors, alone or in combination with agonists
such as LPS, TNFα or IL-1β, increased the expression of known NF-κB
target genes, including pro-inﬂammatorymediators or regulators of ap-
optosis. As remarked above, such observations need to be interpreted
with caution because of the imperfect speciﬁcity of the compounds as
PP2A inhibitors (Swingle et al., 2007). However, there is awealth of cor-
roborating evidence. Expression of SV40 small T antigen also activated
NF-κB (Moreno et al., 2004; E. Sontag, Sontag, & Garcia, 1997). PP2A
physically interacts with the IKK complex, IκBα and RelA itself and
can catalyse the removal of phosphates that are required for the activa-
tion or proteolytic processing of these proteins (DiDonato, Hayakawa,
Rothwarf, Zandi, & Karin, 1997; Li, Wang, Berman, Zhang, & Dorf,
2006; Tsuchiya et al., 2017; J. Yang, Fan, Wadzinski, Sakurai, &
Richmond, 2001). Macrophage-speciﬁc disruption of the mouse
Ppp2ca gene enhanced the expression of several inﬂammatory media-
tors in LPS-injected mice, and strongly increased mortality in response
to this challenge (He et al., 2019; L. Sun et al., 2017). LPS-stimulated
Ppp2ca-/- macrophages displayed noticeable prolongation of IKKβ
phosphorylation, andmore dramatic prolongation of RelA Ser536 phos-
phorylation. The phosphorylation of IKKα/β was increased by knock-
down of PPP2CB in astrocytes (Li et al., 2006) or of PPP2CA in KB cells
(Witt et al., 2009). These observations powerfully illustrate the impor-
tant role of PP2A in the limitation of inﬂammatory responses, but do
not yet shed light on mechanisms or speciﬁcity of targeting of the NF-
κB pathway by PP2A at different levels.
A systematic RNA interference (RNAi) screen was used to identify
phosphatase components that regulate the NF-κB pathway in a mouse
astrocyte cell line. NF-κB activity was enhanced by knock-down of the
B subunit PPP2R5C (as well as by knock-down of scaffolding and cata-
lytic subunits) (Li et al., 2006). PPP2R5C was reported to mediate de-
phosphorylation of a novel activatory phosphorylation site in TRAF2,
Thr117 (Li, Wang, & Dorf, 2009). Knock-down of PPP2R5C also de-
creased IκBα levels in human embryonic kidney cells, consistent with
activation of NF-κB signaling (Moreno et al., 2004). In another RNAi
screen (Breuer et al., 2014), knock-down of PPP2R5C in a T cell line en-
hanced the activation of an NF-κB reporter construct by TNF, 12-O-
tetradecanoylphorbol-13-acetate or T cell receptor engagement,
whereas over-expression of the same B subunit decreased NF-κBactivity and the expression of IL-2. TCR engagement increased the ex-
pression of PPP2R5C, presumably as a negative feedback mechanism
limiting the duration of the NF-κB activation response. Knock-down of
PPP2R5C increased the phosphorylation of IKKα/β, suggesting that the
site of action is at this level or above. Mathematical modeling of the
NF-κB signaling pathway implied that PP2A constitutively associates
with and negatively regulates the IKK complex in KB cells (Witt et al.,
2009). However, in dendritic cells de novo gene expressionwas required
for PP2A to interact with the IKK complex and promote IKKα/β dephos-
phorylation (Chang, Voorhees, Liu, Zhao, & Chang, 2010). One obvious
interpretation is that LPS induces the expression of a B subunit that is es-
sential for targeting of PP2A to IKK and terminating the activation of the
NF-κB pathway. However, the systematic RNAi screens described above
did not conclusively identify an IKK targeting factor (Breuer et al., 2014;
Li et al., 2006). An over-expression approach in HEK293 (a human kid-
ney cancer cell line) implicated members of the STRN family as possible
IKK targeting B subunits (Tsuchiya et al., 2017). This awaits corrobora-
tion by knock-out or knock-down methods.
NF-κB-dependent genes are differentially affected by variations in
the dynamics of NF-κB activation (Brasier, 2006), providing a mecha-
nismbywhich PP2A can exert gene-speciﬁc effects. For example in den-
dritic cells PP2A prevents sustained activation of the IKK complex and
NF-κB, inhibiting the expression of Il23bwithout inﬂuencing expression
of other members of the IL-12 family (Chang et al., 2010). In contrast,
the interaction between PP2A and the IKK complex is targeted by the
human T-lymphotropic virus 1 transcriptional activation protein Tax,
promoting sustained IKK activation and NF-κB mediated transcription
from the viral long terminal repeat (Fu, Kuo, Liu, Jeang, & Giam, 2003;
Hong et al., 2007). Ultraviolet B radiation (UVB) impairs PP2A-
mediated dephosphorylation and inactivation of IKKα/β, prolonging
NF-κB activation. This contributes to cooperative regulation of TNF
and other NF-κB target genes by IL-1 and UVB (Barisic, Strozyk, Peters,
Walczak, & Kulms, 2008; Witt et al., 2009). The mechanism of inactiva-
tion of PP2A by UVB is not known, but is thought to be indirect (Witt
et al., 2009).
There is increasing evidence that PP2A also directly targets RelA to
control the duration of NF-κB activation. First, PP2A interacts with
RelA and promotes its dephosphorylation (Hsieh, Hsiao, Hsu, Wang, &
Sheu, 2014; Yang et al., 2001). Plant-derived anti-inﬂammatory com-
pounds have been shown to decrease the phosphorylation of RelA at
Ser576, apparently without inﬂuencing upstream signaling events
(Hsieh et al., 2011; Hsieh et al., 2014; Shu et al., 2016). Although the
basis of targeting of RelA by PP2A is not yet known, an endogenous fac-
tor that inﬂuences this process has been identiﬁed (Zhang, Park, et al.,
2013). Pleckstrin homology domain ﬁnger protein 20 recognizes meth-
ylated Lys221 of RelA, protecting RelA against PP2A-mediated dephos-
phorylation of Ser576, and thereby prolonging NF-κB activity in the
nucleus.
PP2Amay exert subtle cell type-, gene- and stimulus-speciﬁc effects
on gene expression by regulating inﬂammatory signaling at several
levels, modulating the dynamics of NF-κB activation and inactivation
rather than imposing a simple on/off switch. PP2A dephosphorylates
and inactivates TAK1 to negatively regulate TGFβ1 signaling in
mesangial cells (Kim, Kwak, Wang, & Choi, 2008), but has not yet
been shown to regulate NF-κB activation via TAK1. Identiﬁcation of
targeting mechanims in the NF-κB pathway remains challenging, per-
haps because of redundancy between B subunits, or because important
mediators of PP2A substrate speciﬁcity have yet to be identiﬁed. Finally,
impaired PP2A function anddysregulatedNF-κB activitymay contribute
to pathological conditions such as viral replication and oncogenic trans-
formation (Guergnon et al., 2011; Taniguchi & Karin, 2018). It is also
worth noting that myeloid-speciﬁc disruption of the Ppp2ca gene re-
sulted in over-expression of Interferon β and interferon-regulated
genes, which was attributed to enhanced function of NF-κB, a known
transcriptional regulator of the Ifnb1 gene (Sun et al., 2017). There
may be an involvement of the transcription factor IRF3, which also
189A.R. Clark, M. Ohlmeyer / Pharmacology & Therapeutics 201 (2019) 181–201promotes Ifnb1 transcription, and is activated via phosphorylation
downstream of recruitment of the adaptor protein TRIF to TLR4 and
other PRRs at the endosomal compartment. PP2Awas shown tomediate
dephosphorylation and inactivation of IRF3, with the involvement of
two unexpected adapter proteins, receptor for activated C kinase 1
(Long et al., 2014) and F-box protein 17 (D. Peng, Wang, Huang, Zhao,
& Qin, 2017).
4.3. MAPKs (mitogen-activated protein kinases)
Downstreamof TLR4 engagement, TAK-1 directly or indirectlymedi-
ates the activation of various mitogen-activated protein kinase kinases
(MKKs) (Arthur & Ley, 2013; Pattison et al., 2016). In turn, these dual
speciﬁcity kinases phosphorylate their substrate MAPKs at closely
spaced threonine and tyrosine residues, causing activation. Of the
three classical MAPK families, p38 and JNK (cJun N-terminal kinase)
are intimately linked to the regulation of inﬂammatory gene expression,
whereas ERK (extracellular signal-regulated kinase) appears to play a
less prominent role in inﬂammatory responses (Arthur & Ley, 2013).
MAPKp38 controls expression of inﬂammatory genes via the phosphor-
ylation of transcription factors and via the regulation of mRNA stability
(see below). As its name implies, JNK is largely responsible for the
activation of c-Jun via phosphorylation of serines 63 and 73 within its
N-terminal transcriptional activation domain. As one component of
the dimeric transcription factor AP-1 (activator protein 1), c-Jun
contributes to the transcriptional activation of large numbers of pro-
inﬂammatory mediators, often functioning collaboratively with tran-
scription factors of the ETS (E twenty-six), IRF (interferon-regulatory
factor) and NF-κB families (Natoli, Ghisletti, & Barozzi, 2011; Peng,
2008; Wagner, 2010). Aberrant activation of the JNK pathway has
been implicated in pathogenesis of several diseases, including some
inﬂammation-associated cancers and meta-inﬂammation associated
with insulin resistance (Sabapathy, 2012).
The activation of MAPKs in response to pro-inﬂammatory stimuli is
enhanced and/or prolonged when PP2A function is compromised by
pharmacological inhibition, knock-down or knock-out of catalytic sub-
units, or overexpression of inhibitors. This leads to enhanced expression
of inﬂammatorymediators including cytokines, chemokines andmetal-
loproteinases (Al-Murrani, Woodgett, & Damuni, 1999; He et al., 2019;
Kamat, Rai, Swarnkar, Shukla, & Nath, 2014; Law, Tam, Lee, & Lau,
2013; Rahman et al., 2015; Shanley, Vasi, Denenberg, & Wong, 2001;
Sun et al., 2017; Wang et al., 2017; Westermarck, Holmstrom, Ahonen,
Eriksson, & Kahari, 1998). In several cases, an increase in JNK-
mediated activation of AP-1 has been implicated in the augmented in-
ﬂammatory responses. Consistent with this proposed mechanism,
PP2A interacts with JNK and its upstream activator MKK4 (Avdi,
Malcolm,Nick, &Worthen, 2002; Zhao et al., 2008). As an added compli-
cation, nuclear PP2A complexes containing the B subunit PPP2R2A can
reverse the phosphorylation of cJun at threonine 239, a post-
translational modiﬁcation that impairs transcriptional activation
(Gilan et al., 2015; Shi et al., 2017). Hence PP2A may either positively
or negatively regulate AP-1 function, depending on the expression of B
subunits and their subcellular localization. Yet another level of complex-
ity is introduced by PP2A-mediated cross-talk between MAPK signaling
pathways. MAPK p38-dependent increase of PP2A activity causes a de-
cline in activity of JNK or ERK (Avdi et al., 2002; Junttila, Li, &
Westermarck, 2008; Liu, Chen, Cheng, Lin, & Chang, 2013; Liu
& Hofmann, 2004; Wang et al., 2006; Westermarck, Li, Kallunki, Han,
& Kahari, 2001). Such cross-talk is likely to involve phosphorylation-
mediated modulation of speciﬁc PP2A holoenzyme complexes, but the
molecular mechanisms are not yet known.
4.4. TTP (Tristetraprolin)
MAPK p38 phosphorylates and activates the downstream kinase
MK2 (MAPK-activated protein kinase 2), which has multiple roles inthe regulation of cellular responses to stress and pro-inﬂammatory
stimuli (Gaestel, 2013; Menon & Gaestel, 2018). One important down-
stream target is tristetraprolin (TTP), a member of a small family of
zinc ﬁnger mRNA-binding proteins, encoded by the gene Zfp36
(mouse) or ZFP36 (human) (Brooks & Blackshear, 2013). TTP binds in
a sequence-speciﬁc manner to sites closely resembling the sequence
[A/U]UAUUUAU[A/U]. It then recruits several nuclease proteins or pro-
tein complexes, amongst which the most important is the CCR4/NOT
deadenylase complex. This catalyses the progressive removal of the pro-
tective poly-(A) tail, the rate-limiting step in the degradation of most
mRNA species (Carpenter, Ricci, Mercier, Moore, & Fitzgerald, 2014;
Newman, McHugh, & Turner, 2016). Cognate binding sites for TTP are
commonly found in the 3’ untranslated regions of mRNAs that encode
pro-inﬂammatory mediators, as well as regulators of cell cycle progres-
sion. Therefore, just as NF-κB is a master transcriptional regulator of in-
ﬂammatory responses, TTP can be considered as a master negative
regulator of inﬂammatory responses at the post-transcriptional level
(Brooks & Blackshear, 2013). Germline disruption of the Zfp36 gene
causes a severe inﬂammatory syndrome characterized by increased sta-
bility of many pro-inﬂammatory transcripts and over-expression of
their products, most notably tumor necrosis factor α (TNFα)
(Carballo, Gilkeson, & Blackshear, 1997; Carballo, Lai, & Blackshear,
1998; Taylor et al., 1996).
TTP is very extensively post-translationally modiﬁed, with at least
thirty well-documented sites of phosphorylation (Cao et al., 2006;
Clark & Dean, 2016; O'Neil, Ammit, & Clark, 2018; Sandler & Stoecklin,
2008). Little or nothing is known about the mechanisms and conse-
quences of most of these phosphorylations. However, MK2 is known
to mediate the phosphorylation of three sites, namely Ser52, Ser178
and Ser316 (Chrestensen et al., 2004; Hitti et al., 2006; Stoecklin et al.,
2004). Ser316 is within a highly conserved C-terminal domain that is
critical for regulation of mRNA stability by TTP and its close relatives
(Blackshear & Perera, 2014). The phosphorylation of this site is thought
to impair the mRNA-destabilizing function of TTP, although themecha-
nismhas not yet been fully characterized (Fabian et al., 2013). The phos-
phorylation of Ser52 and Ser178 facilitates binding of TTP by 14-3-3
proteins (Chrestensen et al., 2004), adaptors that speciﬁcally recognise
the phosphorylated forms of their client proteins (Mackintosh, 2004;
Wilker & Yaffe, 2004). The recruitment of 14-3-3 proteins impairs the
interaction of TTP with the CCR4/NOT complex, thus promoting stabili-
zation of mRNAs that would otherwise be targeted for rapid degrada-
tion (Marchese et al., 2010; Sandler, Kreth, Timmers, & Stoecklin,
2011; Stoecklin et al., 2004; Sun et al., 2007).
Because it lacks deﬁned structure outside of its central RNA-binding
domain, TTP protein tends to be rapidly turned over by a proteasome-
mediated but ubiquitination-independent unfolded protein degrada-
tion pathway (Ngoc et al., 2014). A second consequence of the
phosphorylation of Ser52 and Ser178 is protection of TTP against this
process (Brook et al., 2006; Hitti et al., 2006; Ngoc et al., 2014). 14-3-3
proteins are known to impose stable structure upon their phosphory-
lated client proteins (Yaffe, 2002). It remains to be demonstrated that
14-3-3 protein recruitment mediates the stabilization of TTP in re-
sponse to its phosphorylation (Clark & Dean, 2016; Ngoc et al., 2014).
In any case, the result of the coupled, phosphorylation-mediated stabi-
lization and inactivation of TTP protein is that there is often an inverse
relationship between the amount of TTP present and its activity. For ex-
ample, in cells where the MAPK p38 pathway is dysregulated, phos-
phorylated TTP accumulates and TTP-regulated pro-inﬂammatory
mRNAs are abnormally stable, resulting in exaggerated inﬂammatory
responses (Abraham & Clark, 2006; Clark & Dean, 2016; Smallie et al.,
2015). Similarly, okadaic acid treatment of airway epithelial cells in-
creased the expression of the TTP targets IL-6 and IL-8, despite also in-
creasing the expression of TTP protein (presumably in its
phosphorylated and inactive form) (Rahman et al., 2015). Conversely,
if TTP phosphorylation is blocked by targeted germline mutation of co-
dons 52 and 178 of the mouse Zfp36 gene, TTP protein is weakly
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as Zfp36aa/aa) are signiﬁcantly protected in several experimental
models of inﬂammatory pathology, including LPS-induced endotoxemia
(O'Neil et al., 2017; Ross et al., 2015; Tang et al., 2017), zymosan-
induced air pouch inﬂammation, experimental arthritis (Ross et al.,
2017), cigarette smoke-induced airway inﬂammation and
polymicrobial sepsis (unpublished observations).
The unusual relationship between quantity and activity of TTP may
help to explain the otherwise puzzling observation, that TTP protein is
abundant at sites of chronic inﬂammation such as the rheumatoid
synovium or atherosclerotic plaque (Brooks, Connolly, Diegel, Fava, &
Rigby, 2002; Ross et al., 2017; Zhang, Taylor et al., 2013). We have hy-
pothesized that accumulation of phosphorylated, inactive TTP contrib-
utes to the establishment of chronic inﬂammation in vivo (Clark &
Dean, 2016; Ross et al., 2017). TTP has also been identiﬁed as a putative
tumor suppressor (Park, Lee, & Kang, 2018; Ross, Brennan-Laun, &Wil-
son, 2012; Sanduja, Blanco, Young, Kaza, & Dixon, 2012). It negatively
regulates several genes that are involved in tumor progression, includ-
ing cMyc (Rounbehler et al., 2012), a transcription factor that coordi-
nates metabolic reprogramming of cancer cells (Carroll, Freie,
Mathsyaraja, & Eisenman, 2018; Dejure & Eilers, 2017); and pro-
grammed death ligand 1 (Coelho et al., 2017), a cell surface molecule
that aids immune evasion by tumors (Blank, Gajewski, & Mackensen,
2005; Dong, Sun, & Zhang, 2017; Muenst, Soysal, Tzankov, & Hoeller,
2015). Excessive phosphorylation and inactivation of TTP is thought to
contribute to tumorigenesis (Coelho et al., 2017; Suswam et al., 2013;
Tran et al., 2016).
TTP is efﬁciently dephosphorylated by PP2A (Mahtani et al., 2001;
Sun et al., 2007). The dynamic equilibrium between MK2-mediated
phosphorylation (inactivation) and PP2A-mediated dephosphorylation
(activation) of TTP allows precise regulation of rates of degradation of
pro-inﬂammatory mRNAs via the MAPK p38 - MK2 pathway (Clark &
Dean, 2016; Gaestel, 2013; Kratochvill et al., 2011; O'Neil et al., 2018;
Sedlyarov et al., 2016; Smallie et al., 2015; Tiedje et al., 2016). Activation
of TTP may help to explain observations that PP2A inhibitors increased
expression of pro-inﬂammatory genes by stabilizing mRNA rather
than (or as well as) activating transcription (Cornell et al., 2009;
Mahboubi, Young, & Ferreri, 1997; Sun et al., 2007; Sun et al., 2017;
Sung, Walters, & Fu, 1992; Yoza, Wells, & McCall, 1998). Increased
PP2A activity in ageing B cells was implicated in enhanced TTP-
mediated degradation of Tcf3mRNA, which encodes an important regu-
lator of B cell function (Frasca et al., 2007; Frasca et al., 2010; Frasca,
Landin, Riley, & Blomberg, 2008). Miscontrol of TTP functionmay there-
fore contribute to age-related deﬁcits of B cell function.
The expression of pro-inﬂammatory mediators in airway epithelial
cells was decreased by both FTY720 and its non-phosphorylatable ana-
logue AAL(s), in a TTP-dependent manner (Rahman et al., 2015;
Rahman et al., 2016). We therefore tested the hypothesis that PADs
exert anti-inﬂammatory effects via the activation of TTP (Ross et al.,
2017). The apolipoprotein E-derived peptide COG1410 decreased the
expression of TNF and CXCL2 inwild typemacrophages, but had no sig-
niﬁcant effect on the weak expression of these inﬂammatory mediators
in Zfp36aa/aa macrophages, in which TTP is already constitutively de-
phosphorylated and active. In parallel, COG1410 decreased the expres-
sion of wild type TTP protein but did not inﬂuence the expression of
the non-phosphorylatable mutant TTP protein. COG1410-mediated
suppression of TNF expression was dependent on an intact TTP binding
site in the Tnf 3’UTR (Ross et al., 2017). All of these observations suggest
that COG1410 exerts anti-inﬂammatory effects in vitro by promoting
the dephosphorylation and activation of TTP. Both COG1410 and AAL
(s) exerted therapeutic effects in an experimental model of rheumatoid
arthritis (Ross et al., 2017).
These ﬁndings constitute proof of principle that PADs may exert
anti-inﬂammatory effects at least in part via the activation of TTP. How-
ever, we still know relatively little about the dephosphorylation side of
the TTP equilibrium. In vitro dephosphorylation of TTP was performedusing a commercial preparation that consists mainly of catalytic and
scaffolding subunits (Mahtani et al., 2001; Sun et al., 2007). The involve-
ment of B subunits in the targeting of TTP for dephosphorylation is so far
unexplored. It is not known where in the cell the process takes place. It
is also unclear whether TTP dephosphorylation is constitutive or regu-
lated, for example via changes in expression of the relevant B subunit
(s) or their assembly into holoenzymes.
5. Neuro-inﬂammation and neuro-degeneration
5.1. Introduction
Neuro-inﬂammation is characterized by functional compromise of
the blood–brain barrier (BBB), inﬁltration of the brain by leukocytes
that are otherwise normally excluded, and aberrant activation of glial
(that is, non-neuronal) cells (Laurent, Buee, & Blum, 2018; Skaper,
Facci, Zusso, & Giusti, 2018; Stephenson, Nutma, van der Valk, & Amor,
2018). Glial cells in the brain include oligodendrocytes, whose principal
function is to generate and maintain the insulating myelin sheaths of
neurons; astrocytes, which biochemically and structurally support neu-
ronal and BBB function; and microglia, resident myeloid cells which
serve homeostatic functions in the central nervous system (CNS), par-
ticipate in synaptic remodelling and mediate inﬂammatory responses
to injury or infection. Neuro-inﬂammation is very often accompanied
by neuro-degeneration, causing various degrees of motor, sensory, cog-
nitive and affective symptoms. Neuro-inﬂammation may be either
cause or consequence of neuro-degeneration, and the causal relation-
ships between these two intimately connected, mutually reinforcing
processes can be difﬁcult to establish. Here we will focus on two very
distinct neuro-inﬂammatory and neuro-degenerative conditions in
which PP2A has gained attention for quite different reasons.
5.2. Alzheimer’s disease
The principal cause of dementia is the progressive neuro-
degenerative condition known as Alzheimer’s disease (AD). A deﬁning
histological feature of AD is the presence of extracellular plaques com-
posed of insoluble aggregates of amyloid β peptides, and intracellular
neuroﬁbrillary tangles (NFT) composed of aggregates of tau protein.
Tau is a microtubule-associated protein possessing three to four C ter-
minal tubulin-binding motifs (according to which splice isoform of the
primary transcript is expressed). It regulates synaptic plasticity of neu-
rons by controllingmicrotubule dynamics, and the formation and stabil-
ity of neurotransmitter-activated signaling complexes at the cell
surface. According to the tau hypothesis, the formation of NFTs is the
key pathogenic process driving neuronal dysfunction and death, not
only in AD but also in other neurodegenerative conditions collectively
known as tauopathies (Iqbal et al., 2010; Sabbagh & Dickey, 2016;
Sontag & Sontag, 2014; Voronkov, Braithwaite, & Stock, 2011; Ward,
Himmelstein, Lancia, & Binder, 2012). In this scenario, amyloid plaque
formation in AD is secondary to NFT-mediated neurodegeneration, al-
though it may also exacerbate pathology by causing neurodegeneration
in its own right, promoting the activation of resident glial cells and the
recruitment of inﬂammatory monocytes from the circulation. Interac-
tions of tau with tubulin are regulated by phosphorylation of sites that
ﬂank the tubulin-binding domain. Several kinases have been implicated
in tau phosphorylation; notably glycogen synthase kinase 3β, cyclin-
dependent kinase 5 and extracellular signal-regulated kinase 2.
Hyper-phosphorylation leads to impairment of the normal physiologi-
cal functions of tau, its oligomerization, and ultimately the formation
of NFTs. One possible approach to treatment of AD is to inhibit kinases
responsible for tau hyperphosphorylation. At the time of writing, clini-
cal trials of a glycogen synthase kinase 3β inhibitor are ongoing (del
Ser et al., 2013; Lovestone et al., 2015; Medina, Garrido, & Wandosell,
2011).
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can be attributed to PP2A holoenzyme that contains the speciﬁcity sub-
unit PPP2R2A (Liu, Grundke-Iqbal, Iqbal, & Gong, 2005; Martin et al.,
2013; Sontag et al., 1999). The structure of this holoenzyme complex
has been solved, providing important insights into the mechanism of
targeting tau for dephosphorylation (Xu, Chen, Zhang, Jeffrey, & Shi,
2008). As previously remarked, the incorporation of members of the
PPP2R2 family into the PP2A holoenzyme is dependent on carboxy
terminal methylation of the catalytic subunit PPP2CA, and sensitive to
perturbations that inhibit this post-translational modiﬁcation. Tau
hyper-phosphorylation and some AD-like features can be caused or ex-
acerbated by experimental manipulation of PP2A activity, for example
using PP2A-inhibiting chemicals (Gong, Wang, Iqbal, & Grundke-Iqbal,
2003; Kamat, Rai, & Nath, 2013), over-expression of DNA tumor virus
T antigens (Sontag, Nunbhakdi-Craig, Lee, Bloom, & Mumby, 1996) or
PP2A inhibitory proteins (Wang, Blanchard, Tung, Grundke-Iqbal, &
Iqbal, 2015), introduction of a dominant negative catalytic subunit
(Deters, Ittner, & Gotz, 2009) or inhibition of PP2CA methylation
(Sontag, Nunbhakdi-Craig, & Sontag, 2013). Conversely, PP2A activity
is reportedly reduced by about 50% in AD-affected CNS tissue. As
reviewed in detail elsewhere (Sontag & Sontag, 2014; Voronkov et al.,
2011), several differentmechanisms of PP2A dysfunction have been de-
scribed in AD. These include: decreased expression of the PPP2R2A sub-
unit; increased expression or altered subcellular localization of
endogenous PP2A inhibitor proteins; decreased expression, reduced
Leu309 methylation. Increased Tyr307 phosphorylation of the catalytic
subunit of PP2A has also been described, although as noted above
these observations need to be interpreted with caution.
Evidence of PP2A dysfunction has prompted researchers to investi-
gate therapeutic responses to PADs in experimental models of AD. Cog-
nitive impairment driven by amyloid β aggregates was reduced
following treatment of animals with the novel PP2A-activating com-
pound EHT (Asam et al., 2017; Basurto-Islas et al., 2014) or FTY720
(Asle-Rousta, Kolahdooz, Dargahi, Ahmadiani, & Nasoohi, 2014; Asle-
Rousta, Kolahdooz, Oryan, Ahmadiani, & Dargahi, 2013; Hemmati
et al., 2013). Sodium selenate, which increases PP2A activity, reduced
cognitive impairment in a PP2A-dependent manner in AD models
based on dysregulated tau phosphorylation (Corcoran et al., 2010; van
Eersel et al., 2010). A copper ionophore, CuII(gtsm), conferred functional
protection in both amyloid β- and tau-mediated models of AD (Crouch
et al., 2009; McKenzie-Nickson et al., 2018). This compound increased
the expression of the scaffolding subunit PPP2R1A in mouse brain, but
increased PP2A activity remains to be demonstrated. Mechanistic stud-
ies of these compounds have focused on neurotoxicity. For example,
FTY720 antagonised amyloid β-induced neuronal death (Aytan et al.,
2016; Doi et al., 2013; Hemmati et al., 2013; Joshi et al., 2017; Ruiz
et al., 2014) in a manner that depended on sphingosine kinase activity,
and was opposed by S1P receptor antagonists (Asle-Rousta et al., 2014;
Joshi et al., 2017). These ﬁndings suggest that phosphorylated FTY720
may exert beneﬁcial effects on neurons via agonistic rather than antag-
onistic action at S1PR1. In the context of AD, there remains a gap in
knowledge about effects of FTY720 and other putative PADs on glial
cells.
5.3. Multiple sclerosis and other neuro-inﬂammatory disorders
MS is a chronic immune-mediated inﬂammatory disease in which
auto-reactive lymphocytes participate in destruction of the insulating
myelin sheaths of neurons, causing neurological dysfunction, pain and
physical disability (Brinkmann et al., 2010; Chaudhry et al., 2017;
Mehling et al., 2011). FTY720 reduced neuro-inﬂammation and neuro-
logical deﬁcits in experimental autoimmune encephalopathy (EAE), a
widely used animal model of MS (Brinkmann et al., 2002; Kataoka
et al., 2005). Following successful clinical trials, it was licensed for use
in the relapsing remitting form of MS. Its annual sales now exceed two
billion dollars, and it is under consideration as a possible treatment forother CNS pathologies such as cerebral ischemia, traumatic CNS injury,
epilepsy and Parkinson’s disease (Huwiler & Zangemeister-Wittke,
2018). According to the orthodox narrative, FTY720 exerts anti-
inﬂammatory effects by blocking lymphocyte egress from lymph
nodes, causing peripheral lymphopenia and interrupting trafﬁc to the
CNS of auto-reactive T cells (Brunkhorst, Vutukuri, & Pfeilschifter,
2014; Chun & Hartung, 2010; Cohen & Chun, 2011; Mehling et al.,
2011). However, in MS, other neuroinﬂammatory pathologies and
their experimental models, there is often a poor correlation between
lymphopenia and the beneﬁcial effects of FTY720 and related com-
pounds, suggesting that additional mechanism of action are likely to
be important (Choi et al., 2011; Foster et al., 2007; Healy, Michell-
Robinson, & Antel, 2015; La Mantia et al., 2016; Rothhammer et al.,
2017; Serdar et al., 2016). In fact, beneﬁcial effect of FTY720 have been
demonstrated in a variety of CNS resident cells, including astrocytes,mi-
croglia, oligodendrocytes and vascular endothelial cells (Groves, Kihara,
& Chun, 2013; Miron, Schubart, & Antel, 2008). It remains a subject of
lively debate, whether these are mediated by agonistic or antagonistic
effects of phosphorylated FTY720 on S1P receptors. The possibility
that activation of PP2A contributes to therapeutic effects of FTY720 is
not often considered.
In a variant EAE model, astrocyte-speciﬁc deletion of the gene
encoding S1PR1 both reduced the severity of disease and ablated thera-
peutic responses to FTY720 (Choi et al., 2011). These observations sug-
gest that S1P mediates pathogenic activation of astrocytes via S1PR1,
and that FTY720 exerts protective effects via blockade of the S1P-
S1PR1 axis. However, other researchers implicated S1PR3 as a mediator
of pro-inﬂammatory responses of astrocytes to S1P. This receptor sig-
nals via Gα12/13 to activate the small GTPase RhoA and the transcription
factor NF-κB (Dusaban et al., 2013; Dusaban, Chun, Rosen, Purcell, &
Brown, 2017), a mechanism essentially similar to that previously de-
scribed in vascular endothelial cells (Fernandez-Pisonero et al., 2012;
Keul et al., 2011; Sanchez et al., 2007; Skoura et al., 2011). Activation
of NF-κB is essential for pro-inﬂammatory gene expression by astro-
cytes (Brambilla et al., 2005; van Loo et al., 2006). Global effects of
FTY720 on the astrocyte transcriptome were consistent with inhibition
of NF-κB activation (Rothhammer et al., 2017), and indeed FTY720 im-
paired the activation of NF-κB in astrocytes following stimulation with
S1P or LPS (Colombo et al., 2014; Rothhammer et al., 2017). But here
the links between FTY720 and astrocyte inﬂammatory gene expression
seem to break down. S1PR3 is not thought to be a target of functional
antagonism by FTY720 (Brinkmann et al., 2002; Graler & Goetzl,
2004); and S1PR1, which signals primarily via Gi, does not have a
well-established mechanism of coupling to NF-κB (Siehler & Manning,
2002). Therefore it is unclear whether inhibition of NF-κB is the main
mechanism by which FTY720 decreases expression of inﬂammatory
mediators in astrocytes, and if it is, how this inhibition is achieved.
In MS and other neuro-inﬂammatory pathologies microglia, the res-
ident myeloid cells of the CNS, adopt a pro-inﬂammatory activation
state that is sometimes referred to as “M1” (Baufeld, O'Loughlin,
Calcagno, Madore, & Butovsky, 2018; Mammana et al., 2018; Orihuela,
McPherson, & Harry, 2016; Skaper et al., 2018; Xu, He, & Bai, 2016).
This is accompanied by a metabolic shift in favour of aerobic glycolysis,
which can be detected by positron emission tomography on the basis of
increased uptake of a labelled glucose analogue. FTY720 decreases CNS
glycolytic activity in MS and its experimental models, suggesting a di-
rect anti-inﬂammatory effect on microglia (Airas et al., 2015; Anthony,
Sibson, Losey, Meier, & Leppert, 2014; Sucksdorff et al., 2017). FTY720
inhibited the expression of the pro-inﬂammatory cytokines TNF and
IL-1β in activated primary microglia, microglial cell lines and
microglia-containing organotypic cultures (Das et al., 2017; Jackson,
Giovannoni, & Baker, 2011; Noda, Takeuchi, Mizuno, & Suzumura,
2013; Qin et al., 2017). At the transcriptome level, FTY720 signiﬁcantly
reduced the expression of several hundred genes in LPS-activated pri-
mary microglia (Das et al., 2017). FTY720-induced changes of gene ex-
pression were consistent with skewing from pro-inﬂammatory, “M1”
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tribute to neuro-protection (Giunti, Parodi, Cordano, Uccelli, & Kerlero
de Rosbo, 2014; Kanazawa, Ninomiya, Hatakeyama, Takahashi, &
Shimohata, 2017). There is some evidence that S1P-S1PR1 signaling
promotes pro-inﬂammatory gene expression in microglia (Gaire et al.,
2018), and that FTY720 exerts anti-inﬂammatory effects by disrupting
this axis (Noda et al., 2013). However, the mechanism of anti-
inﬂammatory action of FTY720 in microglia has not been characterized
in detail, and possible involvement of PP2A has not been investigated.
Another myeloid cell type, the dendritic cell (DC), is critically in-
volved in the dysregulated immune responses that underlie MS
(Luessi, Zipp, & Witsch, 2016; Mishra & Yong, 2016). Several groups
have demonstrated inhibitory effects of FTY720 on DC trafﬁc, which
could contribute to beneﬁcial effects of the drug (Gollmann et al.,
2008; Han et al., 2015; Idzko et al., 2006; Lan et al., 2008; Maeda et al.,
2007; Reines et al., 2009). In addition, FTY720 impairs the function of
DCs, reducing their capacity to secrete pro-inﬂammatory cytokines
and stimulate T cell proliferation (Durafourt et al., 2011; Han et al.,
2015; Heng et al., 2010; Idzko et al., 2006; Luessi et al., 2015; Muller
et al., 2005; Ruger et al., 2014; Thomas et al., 2017; Zeng et al., 2012).
In many of these studies FTY720 reduced the expression of IL-12 by ac-
tivated DCs, which is consistent with impairment of Th1 responses.
However, FTY720 was also shown to impair DC-mediated Th2 re-
sponses in an experimental model of asthma (Idzko et al., 2006). In-
triguingly, FTY720 was superior to phospho-FTY720 as an inhibitor of
DC-mediated cytokine expression (Thomas et al., 2017) or T cell activa-
tion (Ruger et al., 2014), an observation that is difﬁcult to reconcile with
an S1PR-mediatedmechanism. PP2Awas tentatively identiﬁed as ame-
diator of the effect of FTY720 on DCs (Ruger et al., 2014), but no detailed
mechanism has yet been described.
Several groups have shown that FTY720 exerts protective effects and
slows functional decline in animal models of Parkinson’s disease (PD)
(Motyl, Przykaza, Boguszewski, Kosson, & Strosznajder, 2018; Ren
et al., 2017; Zhao et al., 2017). One study implicated agonistic effects
of FTY720 on S1PR1 as a therapeutic mechanism (P. Zhao et al., 2017).
However, impairment of PP2A function has been noted in PD and its ex-
perimental models (Braithwaite, Voronkov, Stock, & Mouradian, 2012;
Hua et al., 2015; Park et al., 2016; Taymans & Baekelandt, 2014; Wu
et al., 2012). One group has explored therapeutic effects of FTY720 ana-
logues that activate PP2A but cannot be phosphorylated and do not
cause lymphopenia (Segura-Ulate, Belcher, Vidal-Martinez, Vargas-
Medrano, & Perez, 2017; Vargas-Medrano et al., 2014; Vidal-Martinez
et al., 2016). Other investigators demonstrated protective effects of
the PP2A-activating drug EHT in two different models of PD (Lee et al.,
2011; Lee, Jeong, et al., 2013).
FTY720 reduced lesion size, microglial activation and neurological
deﬁcits in experimental models of stroke or intracerebral hemorrhage
(Brait, Tarrason, Gavalda, Godessart, & Planas, 2016; Czech et al., 2009;
Hasegawa, Suzuki, Sozen, Rolland, & Zhang, 2010; Kraft et al., 2013;
Nazari, Keshavarz, Rafati, Namavar, & Haghani, 2016; Rolland 2nd
et al., 2011; Rolland et al., 2013;Wei et al., 2011). These preclinical ﬁnd-
ings prompted a small clinical trial, which reported promising therapeu-
tic effects of FTY720 in stroke (Fu et al., 2014), and are being followed up
in a larger trial (Fu et al., 2014). The beneﬁcial effects of FTY720 in stroke
and experimentalmodels of brain ischemiawere linked to prevention of
BBB dysfunction (Fu, Zhang, et al., 2014; Kraft et al., 2013; Rolland et al.,
2013;Wei et al., 2011). However, the role of S1PR1 in ischemic brain in-
jury remains controversial, with reports of protective effects of both
S1PR1-selective agonists and antagonists (Brait et al., 2016; Gaire
et al., 2018; Hasegawa, Uekawa, Kawano, Suzuki, & Kim-Mitsuyama,
2017; Sun et al., 2016). To some extent these discrepancies may be ex-
plained by differences between the experimental models used, or
mixed agonist/antagonist properties of the compounds used to manip-
ulate S1PR1 signaling. The possible involvement of PP2A in therapeutic
effects of FTY720 has not been explored in these contexts. However,
protective effects of PP2A-activating peptides have been demonstratedin experimental models of ischemic or physical brain injury (Cao et al.,
2016; Hoane, Kaufman, Vitek, & McKenna, 2009; Kaufman et al., 2010;
Laskowitz et al., 2012; Pang et al., 2017; Qin et al., 2017; Tukhovskaya,
Yukin, Khokhlova, Murashev, & Vitek, 2009; Wu et al., 2016). In some
of these studies, protection of neurological function was accompanied
by prevention of BBB dysfunction (Cao et al., 2016; Pang et al., 2017;
Qin, You, et al., 2017), suggesting at least some degree of overlap be-
tween therapeutic effects of FTY720 and PADs.
6. Remaining questions
In only a little more than a decade, PP2A has emerged as an exciting
therapeutic target in several types of cancer. This approach is being ac-
tively explored by so many research groups in academia and the phar-
maceutical industry, the ﬁrst clinical trials may not be far off.
Dysregulation of tau phosphorylation in Alzheimer’s disease and other
CNSpathologies has placed PP2A in the therapeutic spotlight for slightly
longer. There remain signiﬁcant obstacles to the translation of basic re-
search discoveries in this area, as discussed eloquently elsewhere
(Sontag & Sontag, 2014; Taleski & Sontag, 2018).Many of the same con-
cerns arise when PP2A is considered as a possible therapeutic target in
inﬂammatory diseases. This is a comparatively newconcept, and several
important questions remain to be answered.
6.1. Is PP2A activity impaired in inﬂammatory diseases? And does it
matter?
Reactive oxygen species (ROS) are often abundant at sites of inﬂam-
mation (McGarry, Biniecka, Veale, & Fearon, 2018). Although some ob-
servations are contradictory, there is general consensus that PP2A
activity is impaired by ROS and other radicals, for example via oxidation
of critical thiol groups in the reactive site (Elgenaidi & Spiers, 2019; Jin
Jung et al., 2013; Raman & Pervaiz, 2019; Tan, Shavlakadze, Grounds,
& Arthur, 2015). Prolonged exposure of mice to cigarette smoke in-
creased the expression of the PP2A inhibitor CIP2A, impairing PP2A
function and increasing the expression of metallo-proteinases (Nath
et al., 2018). Increased expression of CIP2Amay contribute to sustained
inﬂammation and tissue damage in chronic obstructive pulmonary dis-
ease (Nath et al., 2018). Elevated CIP2A expression has also been re-
ported in rheumatoid arthritis, where it is thought to contribute to the
abnormal resistance of synovial ﬁbroblasts to apoptosis (Lee et al.,
2012; Lee, Jeong, et al., 2013). As remarked above, pro-inﬂammatory
or immune-stimulatory agonists may also inﬂuence the expression of
B subunits of PP2A (Breuer et al., 2014), suggesting a potential mecha-
nism for ﬁne-tuning of PP2A activity in the context of inﬂammatory or
immune responses.
Overall, remarkably little is known about the regulation or dysregu-
lation of PP2A in inﬂammatory disease. The knowledge gap needs to be
ﬁlled, but it is not necessarily fatal to the concept of therapeutic
targeting of PP2A. A few proof-of-principle experiments have already
shown that PP2A-activating compounds exert therapeutic effects on ex-
perimental inﬂammatory pathologies (Collison et al., 2013; McHugh
et al., 2016; Nair et al., 2017; Ross et al., 2017). Similar effects might
be seen in human inﬂammatory disease, provided that PP2A is not ab-
sent or quantitatively and irreversibly inactivated (both of which
seem unlikely). The expression of PP2A inhibitory proteins at sites of in-
ﬂammation is one important issue that requires further attention, since
many PADs function by interrupting interactions between these pro-
teins and PP2A itself.
6.2. Are all PADs likely to be similar in their effects?
Several PADs speciﬁcally target the inhibitor protein SET; some di-
rectly target the scaffolding subunit PPP2R1A to cause allosteric activa-
tion of the holoenzyme complex; others promote methylation of the
catalytic subunit PPP2CA; and direct catalytic inhibitors of the PP2A
193A.R. Clark, M. Ohlmeyer / Pharmacology & Therapeutics 201 (2019) 181–201inhibitor PME-1 are also under development (Bachovchin et al., 2010).
As discussed above (3.2), differences in mechanism of action of these
compounds are likely to result in different cellular responses to PADs, al-
though to our knowledge this has not yet been demonstrated. Mole-
cules described as PADs also belong to completely different chemical
classes, so that their off-target proﬁles are very likely to differ. Again,
this aspect has not yet been systematically studied.
6.3. Can any therapeutic effects of FTY720 be ascribed to PP2A activation?
FTY720 has a strange double existence in biomedical research. In the
ﬁeld of oncology, FTY720 is well established as a PP2A-activating com-
pound, and it is the foundation of efforts to therapeutically target
PP2A. In the ﬁelds of inﬂammation, neuro-inﬂammation and neuro-
degeneration, FTY720 is widely discussed as a therapeutic tool. Al-
though it is increasingly difﬁcult to explain the beneﬁcial effects of
FTY720 solely in terms of impaired leukocyte trafﬁc, the possible impor-
tance of PP2A activation is very often overlooked. There are adequate
experimental tools to resolve this conundrum. Non-canonical effects
of FTY720 should be independent of sphingosine kinase activity, and
retained by analogues that cannot be phosphorylated. In this context
it is worth noting that AAL(s) failed to reduce symptom severity in
EAE (Brinkmann et al., 2002), an important ﬁnding that argues against
a major role of PP2A as a mediator of protective effects of FTY720 in
this experimental model. It would be valuable to conﬁrm this ﬁnding,
and to extend it by testing effects in EAE of PADs that are unrelated to
FTY720. In principle, selective agonists and antagonists of S1P receptors
should also be useful tools with which to rule in or out the involvement
of S1P-mediated inside out signaling. However, mixed agonistic-
antagonistic effects of such compoundsmay lead to increased confusion
rather than clarity.
6.4. Are PADs likely to be well tolerated?
The inﬂuence of PP2A on cell biology is both broad and deep, giving
rise to very strong concerns about the desirability of indiscriminate
PP2A activation. This is particularly true of chronic but not directly
life-threatening inﬂammatory conditions, in which patients may be ex-
posed to treatments for decades. Most of the pharmacological develop-
ment of PADs has taken place in the cancer domain, where the balance
of beneﬁt against risk is different. Several PADs have demonstrated
in vitro cytotoxic effects on transformed but not on normal cells, and
some have demonstrated favorable safety proﬁles in vivo. But much of
the toxicologywork has been done in relatively short exposure settings,
and most of it in rodent models. There remains a great deal of work to
show whether long term treatment with PADs will be safe in humans.
It may be possible to derive some safety information from drugs that
have already been used extensively in man. The most obvious example
is FTY720, the side effects of which arewell described and broadlyman-
ageable (Jeffery, Rammohan, Hawker, & Fox, 2016; Ward, Jones, &
Goldman, 2014). The methylxanthine drug theophylline and the β ad-
renergic agonists salmeterol and formoterol have been widely used in
the treatment of asthma and chronic obstructive pulmonary disease,
and have also been described as activators of PP2A (Hatchwell et al.,
2014; Kobayashi et al., 2012; Patel et al., 2016; Pullar, Chen, & Isseroff,
2003; Rahman et al., 2016; Sokulsky et al., 2016). On this basis it could
be argued that PADs are likely to be tolerated.
6.5. Is precise targeting preferable to indiscriminate targeting of PP2A?
This is closely connected to some of the preceding questions, and
equally difﬁcult to answer at present. If long-term, global stimulation
of PP2A activity incurs signiﬁcant health risks, then it may ultimately
be possible to mitigate these risks by targeting speciﬁc holoenzyme
complexes, using compounds that interact with the holoenzyme in a
manner dependent on its B subunit. Again, we emphasise theunhelpfulness of discussing PP2A as if it is a single entity. Instead we
need to understand the expression, substrate speciﬁcity and cellular
functions of speciﬁc PP2A holoenzyme complexes (effectively meaning
the expression, speciﬁcity and function of B subunits). In this respect,
there is so far relatively little information in the context of inﬂamma-
tion, and it remains difﬁcult to measure or manipulate the activity of
PP2A in a precise way.
7. Conclusion
There is considerable evidence that PP2A plays an important role in
constraining inﬂammation, and a strong suggestion that some licensed
drugs may exert therapeutic effects at least in part via PP2A activation.
However, the biology of PP2A is so complex that it may never be possi-
ble to fully predict harmful and beneﬁcial effects of PADs. Clinical trials
of these compounds are likely to take place ﬁrst in the cancer ﬁeld,
where the evidence base is strongest and the balance of risk to beneﬁt
most favourable to experimental medicine. If and when such trials do
take place, it would make good sense to monitor potential anti-
inﬂammatory and immune-modulatory effects. And if the safety proﬁles
of PADs are found to be acceptable, there is an argument for rapidly un-
dertaking clinical trials in the context of inﬂammatory disease.
Conﬂict of interest statement
ARC asserts no conﬂict of interest. Mount Sinai School of Medicine
has ﬁled patents on PP2A-activating drugs, including DBK-1154, on be-
half of MO.
Acknowledgements
ARC’s research is supported by Project Grant G0800207 from the
Medical Research Council UK, Programme Grant 21802 from Versus Ar-
thritis, and the Rheumatoid Arthritis Pathogenesis Centre of Excellence
(RACE) award from Versus Arthritis.
References
Abraham, S. M., & Clark, A. R. (2006). Dual-speciﬁcity phosphatase 1: A critical regulator
of innate immune responses. Biochemical Society Transactions 34, 1018–1023.
Agarwal, A., MacKenzie, R. J., Pippa, R., Eide, C. A., Oddo, J., Tyner, J. W., ... Druker, B. J.
(2014). Antagonism of SET using OP449 enhances the efﬁcacy of tyrosine kinase in-
hibitors and overcomes drug resistance in myeloid leukemia. Clinical Cancer
Research 20, 2092–2103.
Ahn, J. H., McAvoy, T., Rakhilin, S. V., Nishi, A., Greengard, P., & Nairn, A. C. (2007). Protein
kinase A activates protein phosphatase 2A by phosphorylation of the B56delta sub-
unit. Proceedings of the National Academy of Sciences of the United States of America
104, 2979–2984.
Airas, L., Dickens, A. M., Elo, P., Marjamaki, P., Johansson, J., Eskola, O., ... Rinne, J. (2015). In
vivo PET imaging demonstrates diminished microglial activation after ﬁngolimod
treatment in an animal model of multiple sclerosis. Journal of Nuclear Medicine 56,
305–310.
Allen-Petersen, B. L., Risom, T., Feng, Z., Wang, Z., Jenny, Z. P., Thoma, M. C., ... Sears, R. C.
(2019). Activation of PP2A and inhibition of mTOR synergistically reduceMYC signal-
ing and decrease tumor growth in pancreatic ductal adenocarcinoma. Cancer
Research 79, 209–219.
Al-Murrani, S. W., Woodgett, J. R., & Damuni, Z. (1999). Expression of I2PP2A, an inhibitor
of protein phosphatase 2A, induces c-Jun and AP-1 activity. The Biochemical Journal
341, 293–298 Pt 2.
Alvarez, S. E., Harikumar, K. B., Hait, N. C., Allegood, J., Strub, G. M., Kim, E. Y., ... Spiegel, S.
(2010). Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase
TRAF2. Nature 465, 1084–1088.
Anthony, D. C., Sibson, N. R., Losey, P., Meier, D. P., & Leppert, D. (2014). Investigation of
immune and CNS-mediated effects of ﬁngolimod in the focal delayed-type hypersen-
sitivity multiple sclerosis model. Neuropharmacology 79, 534–541.
Aoki, M., Aoki, H., Ramanathan, R., Hait, N. C., & Takabe, K. (2016). Sphingosine-1-phos-
phate signaling in immune cells and inﬂammation: roles and therapeutic potential.
Mediators of Inﬂammation 2016, 8606878.
Arnaud, L., Chen, S., Liu, F., Li, B., Khatoon, S., Grundke-Iqbal, I., & Iqbal, K. (2011). Mech-
anism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by
I2(PP2A)/SET. FEBS Letters 585, 2653–2659.
Arthur, J. S., & Ley, S. C. (2013). Mitogen-activated protein kinases in innate immunity.
Nature Reviews. Immunology 13, 679–692.
Asam, K., Staniszewski, A., Zhang, H., Melideo, S. L., Mazzeo, A., Voronkov, M., ... Nicholls, R.
E. (2017). Eicosanoyl-5-hydroxytryptamide (EHT) prevents Alzheimer's disease-
194 A.R. Clark, M. Ohlmeyer / Pharmacology & Therapeutics 201 (2019) 181–201related cognitive and electrophysiological impairments in mice exposed to elevated
concentrations of oligomeric beta-amyloid. PLoS One 12, e0189413.
Asle-Rousta, M., Kolahdooz, Z., Dargahi, L., Ahmadiani, A., & Nasoohi, S. (2014). Promi-
nence of central sphingosine-1-phosphate receptor-1 in attenuating abeta-induced
injury by ﬁngolimod. Journal of Molecular Neuroscience 54, 698–703.
Asle-Rousta, M., Kolahdooz, Z., Oryan, S., Ahmadiani, A., & Dargahi, L. (2013). FTY720
(ﬁngolimod) attenuates beta-amyloid peptide (Abeta42)-induced impairment of
spatial learning and memory in rats. Journal of Molecular Neuroscience 50, 524–532.
Avdi, N. J., Malcolm, K. C., Nick, J. A., & Worthen, G. S. (2002). A role for protein
phosphatase-2A in p38 mitogen-activated protein kinase-mediated regulation of
the c-Jun NH(2)-terminal kinase pathway in human neutrophils. The Journal of
Biological Chemistry 277, 40687–40696.
Aytan, N., Choi, J. K., Carreras, I., Brinkmann, V., Kowall, N. W., Jenkins, B. G., & Dedeoglu, A.
(2016). Fingolimod modulates multiple neuroinﬂammatory markers in a mouse
model of Alzheimer's disease. Scientiﬁc Reports 6, 24939.
Bachovchin, D. A., Speers, A. E., Zuhl, A. M., Brown, S. J., Cravatt, B. F., Fernandez-Vega, V., ...
Rosen, H. R. (2010). Probe Report for PME-1 Inhibitors.
Bachovchin, D. A., Zuhl, A. M., Speers, A. E., Wolfe, M. R., Weerapana, E., Brown, S. J., ...
Cravatt, B. F. (2011). Discovery and optimization of sulfonyl acrylonitriles as selective,
covalent inhibitors of protein phosphatase methylesterase-1. Journal of Medicinal
Chemistry 54, 5229–5236.
Baldacchino, S., Saliba, C., Petroni, V., Fenech, A. G., Borg, N., & Grech, G. (2014). Deregu-
lation of the phosphatase, PP2A is a common event in breast cancer, predicting sen-
sitivity to FTY720. The EPMA Journal 5, 3.
Barisic, S., Strozyk, E., Peters, N., Walczak, H., & Kulms, D. (2008). Identiﬁcation of PP2A as
a crucial regulator of the NF-kappaB feedback loop: its inhibition by UVB turns NF-
kappaB into a pro-apoptotic factor. Cell Death and Differentiation 15, 1681–1690.
Bastan, R., Eskandari, N., Ardakani, H. J., & Peachell, P. H. (2017). Effects of fostriecin on
beta2-adrenoceptor-driven responses in human mast cells. Journal of
Immunotoxicology 14, 60–65.
Basurto-Islas, G., Blanchard, J., Tung, Y. C., Fernandez, J. R., Voronkov, M., Stock, M., ... Iqbal,
K. (2014). Therapeutic beneﬁts of a component of coffee in a rat model of Alzheimer's
disease. Neurobiology of Aging 35, 2701–2712.
Baufeld, C., O'Loughlin, E., Calcagno, N., Madore, C., & Butovsky, O. (2018). Differential
contribution of microglia and monocytes in neurodegenerative diseases. Journal of
Neural Transmission (Vienna) 125, 809–826.
Blackshear, P. J., & Perera, L. (2014). Phylogenetic distribution and evolution of the linked
RNA-binding and NOT1-binding domains in the tristetraprolin family of tandem
CCCH zinc ﬁnger proteins. Journal of Interferon & Cytokine Research 34, 297–306.
Blank, C., Gajewski, T. F., &Mackensen, A. (2005). Interaction of PD-L1 on tumor cells with
PD-1 on tumor-speciﬁc T cells as a mechanism of immune evasion: implications for
tumor immunotherapy. Cancer Immunology, Immunotherapy 54, 307–314.
Brait, V. H., Tarrason, G., Gavalda, A., Godessart, N., & Planas, A. M. (2016). Selective sphin-
gosine 1-phosphate receptor 1 agonist is protective against ischemia/reperfusion in
mice. Stroke 47, 3053–3056.
Braithwaite, S. P., Voronkov, M., Stock, J. B., & Mouradian, M. M. (2012). Targeting phos-
phatases as the next generation of diseasemodifying therapeutics for Parkinson's dis-
ease. Neurochemistry International 61, 899–906.
Brambilla, R., Bracchi-Ricard, V., Hu, W. H., Frydel, B., Bramwell, A., Karmally, S., ... Bethea,
J. R. (2005). Inhibition of astroglial nuclear factor kappaB reduces inﬂammation and
improves functional recovery after spinal cord injury. The Journal of Experimental
Medicine 202, 145–156.
Brasier, A. R. (2006). The NF-kappaB regulatory network. Cardiovascular Toxicology 6,
111–130.
Breuer, R., Becker, M. S., Brechmann,M., Mock, T., Arnold, R., & Krammer, P. H. (2014). The
protein phosphatase 2A regulatory subunit B56gammamediates suppression of T cell
receptor (TCR)-induced nuclear factor-kappaB (NF-kappaB) activity. The Journal of
Biological Chemistry 289, 14996–15004.
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., ... Burtin, P.
(2010). Fingolimod (FTY720): discovery and development of an oral drug to treat
multiple sclerosis. Nature Reviews. Drug Discovery 9, 883–897.
Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., ... Lynch, K. R. (2002).
The immune modulator FTY720 targets sphingosine 1-phosphate receptors. The
Journal of Biological Chemistry 277, 21453–21457.
Brook, M., Tchen, C. R., Santalucia, T., McIlrath, J., Arthur, J. S., Saklatvala, J., & Clark, A. R.
(2006). Posttranslational regulation of tristetraprolin subcellular localization and pro-
tein stability by p38 mitogen-activated protein kinase and extracellular signal-
regulated kinase pathways. Molecular and Cellular Biology 26, 2408–2418.
Brooks, S. A., & Blackshear, P. J. (2013). Tristetraprolin (TTP): Interactions with mRNA and
proteins, and current thoughts onmechanisms of action. Biochimica et Biophysica Acta
1829, 666–679.
Brooks, S. A., Connolly, J. E., Diegel, R. J., Fava, R. A., & Rigby, W. F. (2002). Analysis of the
function, expression, and subcellular distribution of human tristetraprolin. Arthritis
and Rheumatism 46, 1362–1370.
Brunkhorst, R., Vutukuri, R., & Pfeilschifter, W. (2014). Fingolimod for the treatment of
neurological diseases-state of play and future perspectives. Frontiers in Cellular
Neuroscience 8, 283.
Cao, F., Jiang, Y., Wu, Y., Zhong, J., Liu, J., Qin, X., ... Sun, X. (2016). Apolipoprotein e-
mimetic COG1410 reduces acute vasogenic edema following traumatic brain injury.
Journal of Neurotrauma 33, 175–182.
Cao, H., Deterding, L. J., Venable, J. D., Kennington, E. A., Yates, J. R., 3rd, Tomer, K. B., &
Blackshear, P. J. (2006). Identiﬁcation of the anti-inﬂammatory protein tristetraprolin
as a hyperphosphorylated protein by mass spectrometry and site-directed mutagen-
esis. The Biochemical Journal 394, 285–297.
Carballo, E., Gilkeson, G. S., & Blackshear, P. J. (1997). Bonemarrow transplantation repro-
duces the tristetraprolin-deﬁciency syndrome in recombination activating gene-2(-/-) mice. Evidence that monocyte/macrophage progenitors may be responsible for
TNFalpha overproduction. The Journal of Clinical Investigation 100, 986–995.
Carballo, E., Lai,W. S., & Blackshear, P. J. (1998). Feedback inhibition ofmacrophage tumor
necrosis factor-alpha production by tristetraprolin. Science 281, 1001–1005.
Carpenter, S., Ricci, E. P., Mercier, B. C., Moore, M. J., & Fitzgerald, K. A. (2014). Post-
transcriptional regulation of gene expression in innate immunity. Nature Reviews.
Immunology 14, 361–376.
Carratu, M. R., Signorile, A., De Rasmo, D., Reale, A., & Vacca, A. (2016). Pharmacological
activation of protein phosphatase 2 A (PP2A): a novel strategy to ﬁght against
human malignancies? Current Medicinal Chemistry 23, 4286–4296.
Carroll, P. A., Freie, B. W., Mathsyaraja, H., & Eisenman, R. N. (2018). The MYC transcrip-
tion factor network: balancing metabolism, proliferation and oncogenesis. Frontiers
in Medicine 12, 412–425.
Chalfant, C. E., Szulc, Z., Roddy, P., Bielawska, A., & Hannun, Y. A. (2004). The structural re-
quirements for ceramide activation of serine-threonine protein phosphatases. Journal
of Lipid Research 45, 496–506.
Chang, J., Voorhees, T. J., Liu, Y., Zhao, Y., & Chang, C. H. (2010). Interleukin-23 production
in dendritic cells is negatively regulated by protein phosphatase 2A. Proceedings of the
National Academy of Sciences of the United States of America 107, 8340–8345.
Chaudhry, B. Z., Cohen, J. A., & Conway, D. S. (2017). Sphingosine 1-phosphate receptor
modulators for the treatment of multiple sclerosis. Neurotherapeutics 14, 859–873.
Chen, B., Roy, S. G., McMonigle, R. J., Keebaugh, A., McCracken, A. N., Selwan, E., ...
Hanessian, S. (2016). Azacyclic FTY720 analogues that limit nutrient transporter ex-
pression but lack S1P receptor activity and negative chronotropic effects offer a
novel and effective strategy to kill cancer cells in vivo. ACS Chemical Biology 11,
409–414.
Chen, J., Martin, B. L., & Brautigan, D. L. (1992). Regulation of protein serine-threonine
phosphatase type-2A by tyrosine phosphorylation. Science 257, 1261–1264.
Chen, J., Parsons, S., & Brautigan, D. L. (1994). Tyrosine phosphorylation of protein phos-
phatase 2A in response to growth stimulation and v-src transformation of ﬁbroblasts.
The Journal of Biological Chemistry 269, 7957–7962.
Chen, Y., Xu, Y., Bao, Q., Xing, Y., Li, Z., Lin, Z., ... Shi, Y. (2007). Structural and biochemical
insights into the regulation of protein phosphatase 2A by small t antigen of SV40.
Nature Structural & Molecular Biology 14, 527–534.
Cho, U. S., Morrone, S., Sablina, A. A., Arroyo, J. D., Hahn, W. C., & Xu, W. (2007). Structural
basis of PP2A inhibition by small t antigen. PLoS Biology 5, e202.
Cho, U. S., & Xu, W. (2007). Crystal structure of a protein phosphatase 2A heterotrimeric
holoenzyme. Nature 445, 53–57.
Choi, J. W., Gardell, S. E., Herr, D. R., Rivera, R., Lee, C. W., Noguchi, K., ... Chun, J. (2011).
FTY720 (ﬁngolimod) efﬁcacy in an animal model of multiple sclerosis requires astro-
cyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proceedings of the
National Academy of Sciences of the United States of America 108, 751–756.
Chrestensen, C. A., Schroeder, M. J., Shabanowitz, J., Hunt, D. F., Pelo, J. W., Worthington,
M. T., & Sturgill, T. W. (2004). MAPKAP kinase 2 phosphorylates tristetraprolin on
in vivo sites including Ser178, a site required for 14-3-3 binding. The Journal of
Biological Chemistry 279, 10176–10184.
Christensen, D. J., Ohkubo, N., Oddo, J., Van Kanegan, M. J., Neil, J., Li, F., ... Vitek, M. P.
(2011). Apolipoprotein E and peptide mimetics modulate inﬂammation by binding
the SET protein and activating protein phosphatase 2A. Journal of Immunology 186,
2535–2542.
Christian, F., Smith, E. L., & Carmody, R. J. (2016). The Regulation of NF-kappaB Subunits
by Phosphorylation. Cells, 5.
Chun, J., & Hartung, H. P. (2010). Mechanism of action of oral ﬁngolimod (FTY720) in
multiple sclerosis. Clinical Neuropharmacology 33, 91–101.
Clark, A. R., & Dean, J. L. E. (2016). The control of inﬂammation via the phosphorylation
and dephosphorylation of tristetraprolin: a tale of two phosphatases. Biochemical
Society Transactions 44, 1321–1337.
Coelho, M. A., de Carne Trecesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., ...
Downward, J. (2017). Oncogenic RAS signaling promotes tumor immunoresistance
by stabilizing PD-L1 mRNA. Immunity 47, 1083–1099 1086.
Cohen, J. A., & Chun, J. (2011). Mechanisms of ﬁngolimod's efﬁcacy and adverse effects in
multiple sclerosis. Annals of Neurology 69, 759–777.
Collison, A., Hatchwell, L., Verrills, N., Wark, P. A., de Siqueira, A. P., Tooze, M., ... Mattes, J.
(2013). The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-
induced asthma by inhibiting protein phosphatase 2A activity. Nature Medicine 19,
232–237.
Colombo, E., Di Dario, M., Capitolo, E., Chaabane, L., Newcombe, J., Martino, G., & Farina, C.
(2014). Fingolimod may support neuroprotection via blockade of astrocyte nitric
oxide. Annals of Neurology 76, 325–337.
Corcoran, N. M., Martin, D., Hutter-Paier, B., Windisch, M., Nguyen, T., Nheu, L., ... Hovens,
C. M. (2010). Sodium selenate speciﬁcally activates PP2A phosphatase, dephosphor-
ylates tau and reverses memory deﬁcits in an Alzheimer's disease model. Journal of
Clinical Neuroscience 17, 1025–1033.
Cornell, T. T., Hinkovska-Galcheva, V., Sun, L., Cai, Q., Hershenson, M. B., Vanway, S., &
Shanley, T. P. (2009). Ceramide-dependent PP2A regulation of TNFalpha-induced
IL-8 production in respiratory epithelial cells. American Journal of Physiology. Lung Cel-
lular and Molecular Physiology 296, L849–L856.
Cristobal, I., Madoz-Gurpide, J., Manso, R., Gonzalez-Alonso, P., Rojo, F., & Garcia-Foncillas,
J. (2016). Potential anti-tumor effects of FTY720 associated with PP2A activation: a
brief review. Current Medical Research and Opinion 32, 1137–1141.
Cristobal, I., Manso, R., Rincon, R., Carames, C., Senin, C., Borrero, A., ... Garcia-Foncillas, J.
(2014). PP2A inhibition is a common event in colorectal cancer and its restoration
using FTY720 shows promising therapeutic potential. Molecular Cancer Therapeutics
13, 938–947.
Crouch, P. J., Hung, L. W., Adlard, P. A., Cortes, M., Lal, V., Filiz, G., ... Barnham, K. J. (2009).
Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation.
195A.R. Clark, M. Ohlmeyer / Pharmacology & Therapeutics 201 (2019) 181–201Proceedings of the National Academy of Sciences of the United States of America 106,
381–386.
Czech, B., Pfeilschifter, W., Mazaheri-Omrani, N., Strobel, M. A., Kahles, T., Neumann-
Haefelin, T., ... Pfeilschifter, J. (2009). The immunomodulatory sphingosine 1-
phosphate analog FTY720 reduces lesion size and improves neurological outcome
in a mouse model of cerebral ischemia. Biochemical and Biophysical Research
Communications 389, 251–256.
Das, A., Arifuzzaman, S., Kim, S. H., Lee, Y. S., Jung, K. H., & Chai, Y. G. (2017). FTY720
(ﬁngolimod) regulates key target genes essential for inﬂammation in microglial
cells as deﬁned by high-resolution mRNA sequencing. Neuropharmacology 119, 1–14.
Dejure, F. R., & Eilers, M. (2017). MYC and tumor metabolism: chicken and egg. The EMBO
Journal 36, 3409–3420.
Demir, U., Koehler, A., Schneider, R., Schweiger, S., & Klocker, H. (2014). Metformin anti-
tumor effect via disruption of the MID1 translational regulator complex and AR
downregulation in prostate cancer cells. BMC Cancer 14, 52.
Deters, N., Ittner, L. M., & Gotz, J. (2009). Substrate-speciﬁc reduction of PP2A activity ex-
aggerates tau pathology. Biochemical and Biophysical Research Communications 379,
400–405.
DiDonato, J. A., Hayakawa, M., Rothwarf, D. M., Zandi, E., & Karin, M. (1997). A cytokine-
responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature
388, 548–554.
Dobrowsky, R. T., Kamibayashi, C., Mumby, M. C., & Hannun, Y. A. (1993). Ceramide acti-
vates heterotrimeric protein phosphatase 2A. The Journal of Biological Chemistry 268,
15523–15530.
Dodge-Kafka, K. L., Bauman, A., Mayer, N., Henson, E., Heredia, L., Ahn, J., ... Kapiloff, M. S.
(2010). cAMP-stimulated protein phosphatase 2A activity associated with muscle A
kinase-anchoring protein (mAKAP) signaling complexes inhibits the phosphorylation
and activity of the cAMP-speciﬁc phosphodiesterase PDE4D3. The Journal of Biological
Chemistry 285, 11078–11086.
Doi, Y., Takeuchi, H., Horiuchi, H., Hanyu, T., Kawanokuchi, J., Jin, S., ... Suzumura, A.
(2013). Fingolimod phosphate attenuates oligomeric amyloid beta-induced neuro-
toxicity via increased brain-derived neurotrophic factor expression in neurons. PLoS
One 8, e61988.
Dong, Y., Sun, Q., & Zhang, X. (2017). PD-1 and its ligands are important immune check-
points in cancer. Oncotarget 8, 2171–2186.
Durafourt, B. A., Lambert, C., Johnson, T. A., Blain, M., Bar-Or, A., & Antel, J. P. (2011). Dif-
ferential responses of human microglia and blood-derived myeloid cells to FTY720.
Journal of Neuroimmunology 230, 10–16.
Dusaban, S. S., Chun, J., Rosen, H., Purcell, N. H., & Brown, J. H. (2017). Sphingosine 1-
phosphate receptor 3 and RhoA signaling mediate inﬂammatory gene expression in
astrocytes. Journal of Neuroinﬂammation 14, 111.
Dusaban, S. S., Purcell, N. H., Rockenstein, E., Masliah, E., Cho, M. K., Smrcka, A. V., & Brown,
J. H. (2013). Phospholipase C epsilon links G protein-coupled receptor activation to
inﬂammatory astrocytic responses. Proceedings of the National Academy of Sciences
of the United States of America 110, 3609–3614.
Ebenezer, D. L., Fu, P., Suryadevara, V., Zhao, Y., & Natarajan, V. (2017). Epigenetic regula-
tion of pro-inﬂammatory cytokine secretion by sphingosine 1-phosphate (S1P) in
acute lung injury: role of S1P lyase. Advances in Biological Regulation 63, 156–166.
van Eersel, J., Ke, Y. D., Liu, X., Delerue, F., Kril, J. J., Gotz, J., & Ittner, L. M. (2010). Sodium
selenate mitigates tau pathology, neurodegeneration, and functional deﬁcits in
Alzheimer's disease models. Proceedings of the National Academy of Sciences of the
United States of America 107, 13888–13893.
Elgenaidi, I. S., & Spiers, J. P. (2019). Regulation of the phosphoprotein phosphatase 2A
system and its modulation during oxidative stress: a potential therapeutic target?
Pharmacology & Therapeutics 198, 68–89.
Enjeti, A. K., D'Crus, A., Melville, K., Verrills, N. M., & Rowlings, P. (2016). A systematic
evaluation of the safety and toxicity of ﬁngolimod for its potential use in the treat-
ment of acute myeloid leukaemia. Anti-Cancer Drugs 27, 560–568.
Fabian, M. R., Frank, F., Rouya, C., Siddiqui, N., Lai, W. S., Karetnikov, A., ... Sonenberg, N.
(2013). Structural basis for the recruitment of the human CCR4-NOT deadenylase
complex by tristetraprolin. Nature Structural & Molecular Biology 20, 735–739.
Feng, G., Ohmori, Y., & Chang, P. L. (2006). Production of chemokine CXCL1/KC by okadaic
acid through the nuclear factor-kappaB pathway. Carcinogenesis 27, 43–52.
Fernandez-Pisonero, I., Duenas, A. I., Barreiro, O., Montero, O., Sanchez-Madrid, F., &
Garcia-Rodriguez, C. (2012). Lipopolysaccharide and sphingosine-1-phosphate coop-
erate to induce inﬂammatory molecules and leukocyte adhesion in endothelial cells.
Journal of Immunology 189, 5402–5410.
Foster, C. A., Howard, L. M., Schweitzer, A., Persohn, E., Hiestand, P. C., Balatoni, B., ...
Billich, A. (2007). Brain penetration of the oral immunomodulatory drug FTY720
and its phosphorylation in the central nervous system during experimental autoim-
mune encephalomyelitis: consequences for mode of action in multiple sclerosis.
The Journal of Pharmacology and Experimental Therapeutics 323, 469–475.
Frasca, D., Landin, A. M., Alvarez, J. P., Blackshear, P. J., Riley, R. L., & Blomberg, B. B.
(2007). Tristetraprolin, a negative regulator of mRNA stability, is increased in old
B cells and is involved in the degradation of E47 mRNA. Journal of Immunology
179, 918–927.
Frasca, D., Landin, A. M., Riley, R. L., & Blomberg, B. B. (2008). Mechanisms for decreased
function of B cells in aged mice and humans. Journal of Immunology 180, 2741–2746.
Frasca, D., Romero, M., Landin, A. M., Diaz, A., Riley, R. L., & Blomberg, B. B. (2010). Protein
phosphatase 2A (PP2A) is increased in old murine B cells and mediates p38 MAPK/
tristetraprolin dephosphorylation and E47 mRNA instability. Mechanisms of Ageing
and Development 131, 306–314.
Fu, D. X., Kuo, Y. L., Liu, B. Y., Jeang, K. T., & Giam, C. Z. (2003). Human T-lymphotropic
virus type I tax activates I-kappa B kinase by inhibiting I-kappa B kinase-associated
serine/threonine protein phosphatase 2A. The Journal of Biological Chemistry 278,
1487–1493.Fu, Y., Hao, J., Zhang, N., Ren, L., Sun, N., Li, Y. J., ... Shi, F. D. (2014). Fingolimod for the treat-
ment of intracerebral hemorrhage: a 2-arm proof-of-concept study. JAMA Neurology
71, 1092–1101.
Fu, Y., Zhang, N., Ren, L., Yan, Y., Sun, N., Li, Y. J., ... Shi, F. D. (2014). Impact of an immune
modulator ﬁngolimod on acute ischemic stroke. Proceedings of the National Academy
of Sciences of the United States of America 111, 18315–18320.
Fujiki, H., & Suganuma, M. (2009). Carcinogenic aspects of protein phosphatase 1 and 2A
inhibitors. Progress in Molecular and Subcellular Biology 46, 221–254.
Fujiwara, N., Kawasaki, H., Yabe, R., Christensen, D. J., Vitek, M. P., Mizuno, T., ... Ohama, T.
(2013). A potential therapeutic application of SET/I2PP2A inhibitor OP449 for canine
T-cell lymphoma. The Journal of Veterinary Medical Science 75, 349–354.
Gaestel, M. (2013). What goes upmust come down:molecular basis of MAPKAP kinase 2/
3-dependent regulation of the inﬂammatory response and its inhibition. Biological
Chemistry 394, 1301–1315.
Gaire, B. P., Lee, C. H., Sapkota, A., Lee, S. Y., Chun, J., Cho, H. J., ... Choi, J. W. (2018). Iden-
tiﬁcation of sphingosine 1-phosphate receptor subtype 1 (S1P1) as a pathogenic fac-
tor in transient focal cerebral ischemia. Molecular Neurobiology 55, 2320–2332.
Garner, E. F., Williams, A. P., Stafman, L. L., Aye, J. M., Mroczek-Musulman, E., Moore, B. P.,
... Beierle, E. A. (2018). FTY720 decreases tumorigenesis in group 3 medulloblastoma
patient-derived xenografts. Scientiﬁc Reports 8, 6913.
Gilan, O., Diesch, J., Amalia, M., Jastrzebski, K., Chueh, A. C., Verrills, N. M., ... Dhillon, A. S.
(2015). PR55alpha-containing protein phosphatase 2A complexes promote cancer
cell migration and invasion through regulation of AP-1 transcriptional activity.
Oncogene 34, 1333–1339.
Giunti, D., Parodi, B., Cordano, C., Uccelli, A., & Kerlero de Rosbo, N. (2014). Can we switch
microglia's phenotype to foster neuroprotection? Focus on multiple sclerosis.
Immunology 141, 328–339.
Gollmann, G., Neuwirt, H., Tripp, C. H., Mueller, H., Konwalinka, G., Heuﬂer, C., ...
Tiefenthaler, M. (2008). Sphingosine-1-phosphate receptor type-1 agonism impairs
blood dendritic cell chemotaxis and skin dendritic cell migration to lymph nodes
under inﬂammatory conditions. International Immunology 20, 911–923.
Gong, C. X., Wang, J. Z., Iqbal, K., & Grundke-Iqbal, I. (2003). Inhibition of protein phospha-
tase 2A induces phosphorylation and accumulation of neuroﬁlaments in metaboli-
cally active rat brain slices. Neuroscience Letters 340, 107–110.
Graler, M. H., & Goetzl, E. J. (2004). The immunosuppressant FTY720 down-regulates
sphingosine 1-phosphate G-protein-coupled receptors. The FASEB Journal 18,
551–553.
Grech, G., Baldacchino, S., Saliba, C., Grixti, M. P., Gauci, R., Petroni, V., ... Scerri, C. (2016).
Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and thera-
peutic options. Tumour Biology 37, 11691–11700.
Grossman, B. J., Shanley, T. P., Denenberg, A. G., Zhao, B., & Wong, H. R. (2002). Phospha-
tase inhibition leads to activation of IkappaB kinase in murine macrophages.
Biochemical and Biophysical Research Communications 297, 1264–1269.
Grossman, E. A., Ward, C. C., Spradlin, J. N., Bateman, L. A., Huffman, T. R., Miyamoto, D. K.,
... Nomura, D. K. (2017). Covalent ligand discovery against druggable hotspots
targeted by anti-cancer natural products. Cell Chemical Biology 24, 1368–1376 1086.
Groves, A., Kihara, Y., & Chun, J. (2013). Fingolimod: direct CNS effects of sphingosine 1-
phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
Journal of the Neurological Sciences 328, 9–18.
Guergnon, J., Godet, A. N., Galioot, A., Falanga, P. B., Colle, J. H., Cayla, X., & Garcia, A.
(2011). PP2A targeting by viral proteins: a widespread biological strategy from
DNA/RNA tumor viruses to HIV-1. Biochimica et Biophysica Acta 1812, 1498–1507.
Guo, F., Stanevich, V., Wlodarchak, N., Sengupta, R., Jiang, L., Satyshur, K. A., & Xing, Y.
(2014). Structural basis of PP2A activation by PTPA, an ATP-dependent activation
chaperone. Cell Research 24, 190–203.
Gutierrez, A., Pan, L., Groen, R. W., Baleydier, F., Kentsis, A., Marineau, J., ... Aster, J. C.
(2014). Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblas-
tic leukemia. The Journal of Clinical Investigation 124, 644–655.
Haesen, D., Abbasi Asbagh, L., Derua, R., Hubert, A., Schrauwen, S., Hoorne, Y., ... Janssens,
V. (2016). Recurrent PPP2R1A mutations in uterine cancer act through a dominant-
negative mechanism to promote malignant cell growth. Cancer Research 76,
5719–5731.
Haesen, D., Sents, W., Lemaire, K., Hoorne, Y., & Janssens, V. (2014). The basic biology of
PP2A in hematologic cells and malignancies. Frontiers in Oncology 4, 347.
Hait, N. C., Allegood, J., Maceyka, M., Strub, G. M., Harikumar, K. B., Singh, S. K., ... Spiegel, S.
(2009). Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate.
Science 325, 1254–1257.
Han, Y., Li, X., Zhou, Q., Jie, H., Lao, X., Han, J., ... Sun, E. (2015). FTY720 abrogates collagen-
induced arthritis by hindering dendritic cell migration to local lymph nodes. Journal
of Immunology 195, 4126–4135.
Hanahan, D., &Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144,
646–674.
Hasegawa, Y., Suzuki, H., Sozen, T., Rolland, W., & Zhang, J. H. (2010). Activation of sphin-
gosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in
rats. Stroke 41, 368–374.
Hasegawa, Y., Uekawa, K., Kawano, T., Suzuki, H., & Kim-Mitsuyama, S. (2017). Blockage
of central sphingosine-1-phosphate receptor does not abolish the protective effect
of FTY720 in early brain injury after experimental subarachnoid hemorrhage.
Current Drug Delivery 14, 861–866.
Hatchwell, L., Girkin, J., Dun, M. D., Morten, M., Verrills, N., Toop, H. D., ... Mattes, J. (2014).
Salmeterol attenuates chemotactic responses in rhinovirus-induced exacerbation of
allergic airways disease by modulating protein phosphatase 2A. The Journal of
Allergy and Clinical Immunology 133, 1720–1727.
He, Z., Du, L., Ke, Y., Wen, C., & Zhang, Y. (2019). PP2ACalpha of alveolar macrophages is a
novel protective factor for LPS-induced acute respiratory distress syndrome.
Inﬂammation. 42, 1004–1014.
196 A.R. Clark, M. Ohlmeyer / Pharmacology & Therapeutics 201 (2019) 181–201Healy, L. M., Michell-Robinson, M. A., & Antel, J. P. (2015). Regulation of human glia by
multiple sclerosis disease modifying therapies. Seminars in Immunopathology 37,
639–649.
Hemmati, F., Dargahi, L., Nasoohi, S., Omidbakhsh, R., Mohamed, Z., Chik, Z., ... Ahmadiani,
A. (2013). Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease:
comparison with memantine. Behavioural Brain Research 252, 415–421.
Heng, Y., Ma, Y., Yin, H., Duan, L., Xiong, P., Xu, Y., ... Gong, F. (2010). Adoptive transfer of
FTY720-treated immature BMDCs signiﬁcantly prolonged cardiac allograft survival.
Transplant International 23, 1259–1270.
Hitti, E., Iakovleva, T., Brook, M., Deppenmeier, S., Gruber, A. D., Radzioch, D., ... Gaestel, M.
(2006). Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor
necrosis factor mRNA stability and translation mainly by altering tristetraprolin ex-
pression, stability, and binding to adenine/uridine-rich element. Molecular and
Cellular Biology 26, 2399–2407.
Hoane, M. R., Kaufman, N., Vitek, M. P., & McKenna, S. E. (2009). COG1410 improves cog-
nitive performance and reduces cortical neuronal loss in the traumatically injured
brain. Journal of Neurotrauma 26, 121–129.
Hong, S., Wang, L. C., Gao, X., Kuo, Y. L., Liu, B., Merling, R., ... Giam, C. Z. (2007). Heptad
repeats regulate protein phosphatase 2a recruitment to I-kappaB kinase gamma/
NF-kappaB essential modulator and are targeted by human T-lymphotropic virus
type 1 tax. The Journal of Biological Chemistry 282, 12119–12126.
Hornbeck, P. V., Zhang, B., Murray, B., Kornhauser, J. M., Latham, V., & Skrzypek, E. (2015).
PhosphoSitePlus, 2014:mutations, PTMs and recalibrations. Nucleic Acids Research 43,
D512–D520.
Hsieh, C. Y., Hsiao, G., Hsu, M. J., Wang, Y. H., & Sheu, J. R. (2014). PMC, a potent hydro-
philic alpha-tocopherol derivative, inhibits NF-kappaB activation via PP2A but not
IkappaBalpha-dependent signals in vascular smooth muscle cells. Journal of Cellular
and Molecular Medicine 18, 1278–1289.
Hsieh, C. Y., Hsu, M. J., Hsiao, G., Wang, Y. H., Huang, C.W., Chen, S.W., ... Sheu, J. R. (2011).
Andrographolide enhances nuclear factor-kappaB subunit p65 Ser536 dephosphory-
lation through activation of protein phosphatase 2A in vascular smooth muscle cells.
The Journal of Biological Chemistry 286, 5942–5955.
Hu, X., Garcia, C., Fazli, L., Gleave, M., Vitek, M. P., Jansen, M., ... Mulholland, D. J. (2015).
Inhibition of Pten deﬁcient castration resistant prostate cancer by targeting of the
SET - PP2A signaling axis. Scientiﬁc Reports 5, 15182.
Hua, G., Xiaolei, L., Weiwei, Y., Hao, W., Yuangang, Z., Dongmei, L., ... Hui, Y. (2015). Pro-
tein phosphatase 2A is involved in the tyrosine hydroxylase phosphorylation regu-
lated by alpha-synuclein. Neurochemical Research 40, 428–437.
Huang, B., Yang, X. D., Lamb, A., & Chen, L. F. (2010). Posttranslational modiﬁcations of NF-
kappaB: another layer of regulation for NF-kappaB signaling pathway. Cellular
Signalling 22, 1282–1290.
Hung, M. H., & Chen, K. F. (2017). Reprogramming the oncogenic response: SET protein as
a potential therapeutic target in cancer. Expert Opinion on Therapeutic Targets 21,
685–694.
Huwiler, A., & Zangemeister-Wittke, U. (2018). The sphingosine 1-phosphate receptor
modulator ﬁngolimod as a therapeutic agent: recent ﬁndings and new perspectives.
Pharmacology & Therapeutics 185, 34–49.
Idzko, M., Hammad, H., van Nimwegen, M., Kool, M., Muller, T., Soullie, T., ... Lambrecht,
B. N. (2006). Local application of FTY720 to the lung abrogates experimental asthma
by altering dendritic cell function. The Journal of Clinical Investigation 116,
2935–2944.
Iqbal, K., Wang, X., Blanchard, J., Liu, F., Gong, C. X., & Grundke-Iqbal, I. (2010). Alzheimer's
disease neuroﬁbrillary degeneration: pivotal and multifactorial. Biochemical Society
Transactions 38, 962–966.
Jackson, S. J., Giovannoni, G., & Baker, D. (2011). Fingolimod modulates microglial activa-
tion to augment markers of remyelination. Journal of Neuroinﬂammation 8, 76.
Janssens, V., Longin, S., & Goris, J. (2008). PP2A holoenzyme assembly: in cauda venenum
(the sting is in the tail). Trends in Biochemical Sciences 33, 113–121.
Janssens, V., & Rebollo, A. (2012). The role and therapeutic potential of Ser/Thr phospha-
tase PP2A in apoptotic signalling networks in human cancer cells. Current Molecular
Medicine 12, 268–287.
Jeffery, D. R., Rammohan, K. W., Hawker, K., & Fox, E. (2016). Fingolimod: a review of its
mode of action in the context of its efﬁcacy and safety proﬁle in relapsing forms of
multiple sclerosis. Expert Review of Neurotherapeutics 16, 31–44.
Jiang, L., Stanevich, V., Satyshur, K. A., Kong, M., Watkins, G. R., Wadzinski, B. E., ... Xing, Y.
(2013). Structural basis of protein phosphatase 2A stable latency. Nature
Communications 4, 1699.
Jin Jung, K., Hyun Kim, D., Kyeong Lee, E., Woo Song, C., Pal Yu, B., & Young Chung, H.
(2013). Oxidative stress induces inactivation of protein phosphatase 2A, promoting
proinﬂammatory NF-kappaB in aged rat kidney. Free Radical Biology & Medicine 61,
206–217.
Jordens, J., Janssens, V., Longin, S., Stevens, I., Martens, E., Bultynck, G., ... Van Hoof, C.
(2006). The protein phosphatase 2A phosphatase activator is a novel peptidyl-
prolyl cis/trans-isomerase. The Journal of Biological Chemistry 281, 6349–6357.
Joshi, P., Gabrielli, M., Ponzoni, L., Pelucchi, S., Stravalaci, M., Beeg, M., ... Verderio, C.
(2017). Fingolimod limits acute abeta neurotoxicity and promotes synaptic versus
extrasynaptic NMDA receptor functionality in hippocampal neurons. Scientiﬁc
Reports 7, 41734.
Junttila, M. R., Li, S. P., & Westermarck, J. (2008). Phosphatase-mediated crosstalk be-
tween MAPK signaling pathways in the regulation of cell survival. The FASEB Journal
22, 954–965.
Kamat, P. K., Rai, S., & Nath, C. (2013). Okadaic acid induced neurotoxicity: an emerging
tool to study Alzheimer's disease pathology. Neurotoxicology 37, 163–172.
Kamat, P. K., Rai, S., Swarnkar, S., Shukla, R., & Nath, C. (2014). Molecular and cellular
mechanism of okadaic acid (OKA)-induced neurotoxicity: a novel tool for
Alzheimer's disease therapeutic application. Molecular Neurobiology 50, 852–865.Kanazawa, M., Ninomiya, I., Hatakeyama, M., Takahashi, T., & Shimohata, T. (2017). Mi-
croglia and monocytes/macrophages polarization reveal novel therapeutic mecha-
nism against stroke. International Journal of Molecular Sciences 18.
Kastrinsky, D. B., Sangodkar, J., Zaware, N., Izadmehr, S., Dhawan, N. S., Narla, G., &
Ohlmeyer, M. (2015). Reengineered tricyclic anti-cancer agents. Bioorganic &
Medicinal Chemistry 23, 6528–6534.
Kataoka, H., Sugahara, K., Shimano, K., Teshima, K., Koyama, M., Fukunari, A., & Chiba, K.
(2005). FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experi-
mental autoimmune encephalomyelitis by inhibition of T cell inﬁltration. Cellular &
Molecular Immunology 2, 439–448.
Kau, T. R., Schroeder, F., Ramaswamy, S., Wojciechowski, C. L., Zhao, J. J., Roberts, T. M., ...
Silver, P. A. (2003). A chemical genetic screen identiﬁes inhibitors of regulated nu-
clear export of a Forkhead transcription factor in PTEN-deﬁcient tumor cells. Cancer
Cell 4, 463–476.
Kaufman, N. A., Beare, J. E., Tan, A. A., Vitek, M. P., McKenna, S. E., & Hoane, M. R. (2010).
COG1410, an apolipoprotein E-based peptide, improves cognitive performance and
reduces cortical loss following moderate ﬂuid percussion injury in the rat.
Behavioural Brain Research 214, 395–401.
Kauko, O., O'Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., ...
Westermarck, J. (2018). PP2A inhibition is a druggable MEK inhibitor resistance
mechanism in KRAS-mutant lung cancer cells. Science Translational Medicine 10.
Kauko, O., & Westermarck, J. (2018). Non-genomic mechanisms of protein phosphatase
2A (PP2A) regulation in cancer. The International Journal of Biochemistry & Cell
Biology 96, 157–164.
Kaur, A., & Westermarck, J. (2016). Regulation of protein phosphatase 2A (PP2A) tumor
suppressor function by PME-1. Biochemical Society Transactions 44, 1683–1693.
Kawashima, I., & Kirito, K. (2016). Metformin inhibits JAK2V617F activity in MPN cells by
activating AMPK and PP2A complexes containing the B56alpha subunit. Experimental
Hematology 44, 1156–1165 1154.
Keul, P., Lucke, S., von Wnuck Lipinski, K., Bode, C., Graler, M., Heusch, G., & Levkau, B.
(2011). Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/
macrophages in inﬂammation and atherosclerosis. Circulation Research 108, 314–323.
Kharel, Y., Lee, S., Snyder, A. H., Sheasley-O'neill, S. L., Morris, M. A., Setiady, Y., ... Lynch, K.
R. (2005). Sphingosine kinase 2 is required for modulation of lymphocyte trafﬁc by
FTY720. Journal of Biological Chemistry 280, 36865–36872.
Kickstein, E., Krauss, S., Thornhill, P., Rutschow, D., Zeller, R., Sharkey, J., ... Schweiger, S.
(2010). Biguanide metformin acts on tau phosphorylation via mTOR/protein phos-
phatase 2A (PP2A) signaling. Proceedings of the National Academy of Sciences of the
United States of America 107, 21830–21835.
Kim, S. I., Kwak, J. H., Wang, L., & Choi, M. E. (2008). Protein phosphatase 2A is a negative
regulator of transforming growth factor-beta1-induced TAK1 activation in mesangial
cells. The Journal of Biological Chemistry 283, 10753–10763.
Kim, S. M., Roy, S. G., Chen, B., Nguyen, T. M., McMonigle, R. J., McCracken, A. N., ... Edinger,
A. L. (2016). Targeting cancer metabolism by simultaneously disrupting parallel nu-
trient access pathways. The Journal of Clinical Investigation 126, 4088–4102.
Kiuchi, M., Adachi, K., Kohara, T., Teshima, K., Masubuchi, Y., Mishina, T., & Fujita, T.
(1998). Synthesis and biological evaluation of 2,2-disubstituted 2-aminoethanols:
analogues of FTY720. Bioorganic & Medicinal Chemistry Letters 8, 101–106.
Kiyota, M., Kuroda, J., Yamamoto-Sugitani, M., Shimura, Y., Nakayama, R., Nagoshi, H., ...
Taniwaki, M. (2013). FTY720 induces apoptosis of chronic myelogenous leukemia
cells via dual activation of BIM and BID and overcomes various types of resistance
to tyrosine kinase inhibitors. Apoptosis 18, 1437–1446.
Kobayashi, Y., Mercado, N., Miller-Larsson, A., Barnes, P. J., & Ito, K. (2012). Increased cor-
ticosteroid sensitivity by a long acting beta2 agonist formoterol via beta2
adrenoceptor independent protein phosphatase 2A activation. Pulmonary
Pharmacology & Therapeutics 25, 201–207.
Kong, M., Ditsworth, D., Lindsten, T., & Thompson, C. B. (2009). Alpha4 is an essential reg-
ulator of PP2A phosphatase activity. Molecular Cell 36, 51–60.
Kraft, P., Gob, E., Schuhmann, M. K., Gobel, K., Deppermann, C., Thielmann, I., ...
Kleinschnitz, C. (2013). FTY720 ameliorates acute ischemic stroke in mice by reduc-
ing thrombo-inﬂammation but not by direct neuroprotection. Stroke 44, 3202–3210.
Kratochvill, F., Machacek, C., Vogl, C., Ebner, F., Sedlyarov, V., Gruber, A. R., ... Kovarik, P.
(2011). Tristetraprolin-driven regulatory circuit controls quality and timing of
mRNA decay in inﬂammation. Molecular Systems Biology 7, 560.
Kubiniok, P., Finicle, B. T., Piffaretti, F., McCracken, A. N., Perryman, M., Hanessian, S., ...
Thibault, P. (2019). Dynamic phosphoproteomics uncovers signaling pathways mod-
ulated by anti-oncogenic sphingolipid analogs. Molecular & Cellular Proteomics 18,
408–422.
Kunkel, G. T., Maceyka, M., Milstien, S., & Spiegel, S. (2013). Targeting the sphingosine-1-
phosphate axis in cancer, inﬂammation and beyond. Nature Reviews. Drug Discovery
12, 688–702.
La Mantia, L., Tramacere, I., Firwana, B., Pacchetti, I., Palumbo, R., & Filippini, G. (2016).
Fingolimod for relapsing-remitting multiple sclerosis. Cochrane Database of
Systematic Reviews(4), CD009371.
Lambrecht, C., Haesen, D., Sents, W., Ivanova, E., & Janssens, V. (2013). Structure, regula-
tion, and pharmacological modulation of PP2A phosphatases. Methods in Molecular
Biology 1053, 283–305.
Lan, Y. Y., Tokita, D., Wang, Z., Wang, H. C., Zhan, J., Brinkmann, V., & Thomson, A. W.
(2008). Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migra-
tion and homing to secondary lymphoid tissue: association with prolonged allograft
survival. Transplant Immunology 20, 88–94.
Laskowitz, D. T., Lei, B., Dawson, H. N., Wang, H., Bellows, S. T., Christensen, D. J., ... James,
M. L. (2012). The apoE-mimetic peptide, COG1410, improves functional recovery in a
murine model of intracerebral hemorrhage. Neurocritical Care 16, 316–326.
Laurent, C., Buee, L., & Blum, D. (2018). Tau and neuroinﬂammation: what impact for
Alzheimer's disease and tauopathies? Biomedical Journal 41, 21–33.
197A.R. Clark, M. Ohlmeyer / Pharmacology & Therapeutics 201 (2019) 181–201Law, A. H., Tam, A. H., Lee, D. C., & Lau, A. S. (2013). A role for protein phosphatase 2A in
regulating p38 mitogen activated protein kinase activation and tumor necrosis
factor-alpha expression during inﬂuenza virus infection. International Journal of
Molecular Sciences 14, 7327–7340.
Lee, J., Jeong, H., Park, E. J., Hwang, J. W., Huang, B., Bae, E. K., ... Koh, E. M. (2013). CIP2A
facilitates apoptotic resistance of ﬁbroblast-like synoviocytes in rheumatoid arthritis
independent of c-Myc expression. Rheumatology International 33, 2241–2248.
Lee, J., Park, E. J., Hwang, J. W., Oh, J. M., Kim, H., Bae, E. K., ... Koh, E. M. (2012). CIP2A ex-
pression is associated with synovial hyperplasia and invasive function of ﬁbroblast-
like synoviocytes in rheumatoid arthritis. Rheumatology International 32, 2023–2030.
Lee, K. W., Chen, W., Junn, E., Im, J. Y., Grosso, H., Sonsalla, P. K., ... Mouradian, M. M.
(2011). Enhanced phosphatase activity attenuates alpha-synucleinopathy in a
mouse model. The Journal of Neuroscience 31, 6963–6971.
Lee, K. W., Im, J. Y., Woo, J. M., Grosso, H., Kim, Y. S., Cristovao, A. C., ... Mouradian, M. M.
(2013). Neuroprotective and anti-inﬂammatory properties of a coffee component in
the MPTP model of Parkinson's disease. Neurotherapeutics 10, 143–153.
Li, S., Wang, L., Berman, M. A., Zhang, Y., & Dorf, M. E. (2006). RNAi screen inmouse astro-
cytes identiﬁes phosphatases that regulate NF-kappaB signaling. Molecular Cell 24,
497–509.
Li, S., Wang, L., & Dorf, M. E. (2009). PKC phosphorylation of TRAF2 mediates IKKalpha/
beta recruitment and K63-linked polyubiquitination. Molecular Cell 33, 30–42.
Liang, J., Nagahashi, M., Kim, E. Y., Harikumar, K. B., Yamada, A., Huang, W. C., ... Spiegel, S.
(2013). Sphingosine-1-phosphate links persistent STAT3 activation, chronic intesti-
nal inﬂammation, and development of colitis-associated cancer. Cancer Cell 23,
107–120.
Liu, F., Grundke-Iqbal, I., Iqbal, K., & Gong, C. X. (2005). Contributions of protein phospha-
tases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. The European
Journal of Neuroscience 22, 1942–1950.
Liu, Q., & Hofmann, P. A. (2004). Protein phosphatase 2A-mediated cross-talk between
p38 MAPK and ERK in apoptosis of cardiac myocytes. American Journal of Physiology.
Heart and Circulatory Physiology 286, H2204–H2212.
Liu, Q., Zhao, X., Frissora, F., Ma, Y., Santhanam, R., Jarjoura, D., ... Byrd, J. C. (2008). FTY720
demonstrates promising preclinical activity for chronic lymphocytic leukemia and
lymphoblastic leukemia/lymphoma. Blood 111, 275–284.
Liu, R., Zhou, X. W., Tanila, H., Bjorkdahl, C., Wang, J. Z., Guan, Z. Z., ... Pei, J. J. (2008). Phos-
phorylated PP2A (tyrosine 307) is associated with Alzheimer neuroﬁbrillary pathol-
ogy. Journal of Cellular and Molecular Medicine 12, 241–257.
Liu, W. H., Chen, Y. J., Cheng, T. L., Lin, S. R., & Chang, L. S. (2013). Cross talk between
p38MAPK and ERK is mediated through MAPK-mediated protein phosphatase 2A
catalytic subunit alpha and MAPK phosphatase-1 expression in human leukemia
U937 cells. Cellular Signalling 25, 1845–1851.
Long, L., Deng, Y., Yao, F., Guan, D., Feng, Y., Jiang, H., ... Xie, D. (2014). Recruitment of
phosphatase PP2A by RACK1 adaptor protein deactivates transcription factor IRF3
and limits type I interferon signaling. Immunity 40, 515–529.
van Loo, G., De Lorenzi, R., Schmidt, H., Huth, M., Mildner, A., Schmidt-Supprian, M., ...
Pasparakis, M. (2006). Inhibition of transcription factor NF-kappaB in the central ner-
vous system ameliorates autoimmune encephalomyelitis inmice.Nature Immunology
7, 954–961.
Lovestone, S., Boada, M., Dubois, B., Hull, M., Rinne, J. O., Huppertz, H. J., ... del Ser, T.
(2015). A phase II trial of tideglusib in Alzheimer's disease. Journal of Alzheimer's
Disease 45, 75–88.
Luessi, F., Kraus, S., Trinschek, B., Lerch, S., Ploen, R., Paterka, M., ... Witsch, E. (2015).
FTY720 (ﬁngolimod) treatment tips the balance towards less immunogenic
antigen-presenting cells in patients with multiple sclerosis. Multiple Sclerosis 21,
1811–1822.
Luessi, F., Zipp, F., & Witsch, E. (2016). Dendritic cells as therapeutic targets in neuroin-
ﬂammation. Cellular and Molecular Life Sciences 73, 2425–2450.
Maceyka, M., Harikumar, K. B., Milstien, S., & Spiegel, S. (2012). Sphingosine-1-phosphate
signaling and its role in disease. Trends in Cell Biology 22, 50–60.
Mackintosh, C. (2004). Dynamic interactions between 14-3-3 proteins and phosphopro-
teins regulate diverse cellular processes. The Biochemical Journal 381, 329–342.
Maeda, Y., Matsuyuki, H., Shimano, K., Kataoka, H., Sugahara, K., & Chiba, K. (2007). Migra-
tion of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is me-
diated by different receptor subtypes: S1P regulates the functions of murine mature
dendritic cells via S1P receptor type 3. Journal of Immunology 178, 3437–3446.
Mahboubi, K., Young, W., & Ferreri, N. R. (1997). Induction of prostaglandin endoperoxide
synthase-2 by serine-threonine phosphatase inhibition. Journal of Pharmacology and
Experimental Therapeutics 282, 452–458.
Mahtani, K. R., Brook, M., Dean, J. L., Sully, G., Saklatvala, J., & Clark, A. R. (2001). Mitogen-
activated protein kinase p38 controls the expression and posttranslational modiﬁca-
tion of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability.
Molecular and Cellular Biology 21, 6461–6469.
Mammana, S., Fagone, P., Cavalli, E., Basile, M. S., Petralia, M. C., Nicoletti, F., ... Mazzon, E.
(2018). The role of macrophages in neuroinﬂammatory and neurodegenerative path-
ways of Alzheimer's disease, amyotrophic lateral sclerosis, and multiple sclerosis:
pathogenetic cellular effectors and potential therapeutic targets. International
Journal of Molecular Sciences 19.
Mani, R., Chiang, C. L., Frissora, F. W., Yan, R., Mo, X., Baskar, S., ... Muthusamy, N. (2015).
ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, ex-
erts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo. Experimental
Hematology 43, 770–774 772.
Mani, R., Yan, R., Mo, X., Chen, C. S., Phelps, M. A., Klisovic, R., ... Muthusamy, N. (2017).
Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen
species-mediated cytotoxicity in canine B-cell lymphoma. Veterinary and
Comparative Oncology 15, 1115–1118.Marchese, F. P., Aubareda, A., Tudor, C., Saklatvala, J., Clark, A. R., & Dean, J. L. (2010).
MAPKAP kinase 2 blocks tristetraprolin-directed mRNA decay by inhibiting CAF1
deadenylase recruitment. The Journal of Biological Chemistry 285, 27590–27600.
Martin, L., Latypova, X., Wilson, C. M., Magnaudeix, A., Perrin, M. L., & Terro, F. (2013). Tau
protein phosphatases in Alzheimer's disease: the leading role of PP2A. Ageing
Research Reviews 12, 39–49.
Matsuoka, Y., Nagahara, Y., Ikekita, M., & Shinomiya, T. (2003). A novel immunosuppres-
sive agent FTY720 induced Akt dephosphorylation in leukemia cells. British Journal of
Pharmacology 138, 1303–1312.
Mazhar, S., Taylor, S. E., Sangodkar, J., & Narla, G. (2019). Targeting PP2A in cancer: com-
bination therapies. Biochimica et Biophysica Acta, Molecular Cell Research 1866, 51–63.
McClinch, K., Avelar, R. A., Callejas, D., Izadmehr, S., Wiredja, D., Perl, A., ... Galsky, M. D.
(2018). Small-molecule activators of protein phosphatase 2A for the treatment of
castration-resistant prostate cancer. Cancer Research 78, 2065–2080.
McCracken, A. N., McMonigle, R. J., Tessier, J., Fransson, R., Perryman, M. S., Chen, B., ...
Edinger, A. L. (2017). Phosphorylation of a constrained azacyclic FTY720 analog en-
hances anti-leukemic activity without inducing S1P receptor activation. Leukemia
31, 669–677.
McDermott, M. S., Browne, B. C., Conlon, N. T., O'Brien, N. A., Slamon, D. J., Henry, M., ...
O'Donovan, N. (2014). PP2A inhibition overcomes acquired resistance to HER2
targeted therapy. Molecular Cancer 13, 157.
McGarry, T., Biniecka, M., Veale, D. J., & Fearon, U. (2018). Hypoxia, oxidative stress and
inﬂammation. Free Radical Biology & Medicine 125, 15–24.
McHugh, W. M., Russell, W. W., Fleszar, A. J., Rodenhouse, P. E., Rietberg, S. P., Sun, L., ...
Cornell, T. T. (2016). Protein phosphatase 2A activation attenuates inﬂammation in
murine models of acute lung injury. American Journal of Physiology. Lung Cellular
and Molecular Physiology 311, L903–L912.
McKenzie-Nickson, S., Chan, J., Perez, K., Hung, L. W., Cheng, L., Sedjahtera, A., ... Barnham,
K. J. (2018). Modulating protein phosphatase 2A rescues disease phenotype in neuro-
degenerative tauopathies. ACS Chemical Neuroscience 9, 2731–2740.
Medina, M., Garrido, J. J., & Wandosell, F. G. (2011). Modulation of GSK-3 as a therapeutic
strategy on tau pathologies. Frontiers in Molecular Neuroscience 4, 24.
Mehling, M., Kappos, L., & Derfuss, T. (2011). Fingolimod for multiple sclerosis: mecha-
nism of action, clinical outcomes, and future directions. Current Neurology and
Neuroscience Reports 11, 492–497.
Menon, M. B., & Gaestel, M. (2018). MK2-TNF-signaling comes full circle. Trends in
Biochemical Sciences 43, 170–179.
Miron, V. E., Schubart, A., & Antel, J. P. (2008). Central nervous system-directed effects of
FTY720 (ﬁngolimod). Journal of the Neurological Sciences 274, 13–17.
Mishra, M. K., & Yong, V. W. (2016). Myeloid cells - targets of medication in multiple scle-
rosis. Nature Reviews. Neurology 12, 539–551.
Miskolci, V., Castro-Alcaraz, S., Nguyen, P., Vancura, A., Davidson, D., & Vancurova, I.
(2003). Okadaic acid induces sustained activation of NFkappaB and degradation of
the nuclear IkappaBalpha in human neutrophils. Archives of Biochemistry and
Biophysics 417, 44–52.
Moreno, C. S., Ramachandran, S., Ashby, D. G., Laycock, N., Plattner, C. A., Chen, W., ...
Pallas, D. C. (2004). Signaling and transcriptional changes critical for transformation
of human cells by simian virus 40 small tumor antigen or protein phosphatase 2A
B56gamma knockdown. Cancer Research 64, 6978–6988.
Motyl, J., Przykaza, L., Boguszewski, P. M., Kosson, P., & Strosznajder, J. B. (2018).
Pramipexole and ﬁngolimod exert neuroprotection in a mouse model of Parkinson's
disease by activation of sphingosine kinase 1 and Akt kinase.Neuropharmacology 135,
139–150.
Muenst, S., Soysal, S. D., Tzankov, A., & Hoeller, S. (2015). The PD-1/PD-L1 pathway: bio-
logical background and clinical relevance of an emerging treatment target in immu-
notherapy. Expert Opinion on Therapeutic Targets 19, 201–211.
Mukhopadhyay, A., Saddoughi, S. A., Song, P., Sultan, I., Ponnusamy, S., Senkal, C. E., ...
Ogretmen, B. (2009). Direct interaction between the inhibitor 2 and ceramide via
sphingolipid-protein binding is involved in the regulation of protein phosphatase
2A activity and signaling. The FASEB Journal 23, 751–763.
Muller, H., Hofer, S., Kaneider, N., Neuwirt, H., Mosheimer, B., Mayer, G., ... Tiefenthaler, M.
(2005). The immunomodulator FTY720 interferes with effector functions of human
monocyte-derived dendritic cells. European Journal of Immunology 35, 533–545.
Mullershausen, F., Zecri, F., Cetin, C., Billich, A., Guerini, D., & Seuwen, K. (2009). Persistent
signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors.
Nature Chemical Biology 5, 428–434.
Nair, P. M., Starkey, M. R., Haw, T. J., Liu, G., Horvat, J. C., Morris, J. C., ... Hansbro, P. M.
(2017). Targeting PP2A and proteasome activity ameliorates features of allergic air-
way disease in mice. Allergy. 72, 1891–1903.
Nath, S., Ohlmeyer, M., Salathe, M. A., Poon, J., Baumlin, N., Foronjy, R. F., & Geraghty, P.
(2018). Chronic cigarette smoke exposure subdues PP2A activity by enhancing ex-
pression of the oncogene CIP2A. American Journal of Respiratory Cell and Molecular Bi-
ology 59, 695–705.
Natoli, G., Ghisletti, S., & Barozzi, I. (2011). The genomic landscapes of inﬂammation.
Genes & Development 25, 101–106.
Nazari, M., Keshavarz, S., Rafati, A., Namavar, M. R., & Haghani, M. (2016). Fingolimod
(FTY720) improves hippocampal synaptic plasticity and memory deﬁcit in rats fol-
lowing focal cerebral ischemia. Brain Research Bulletin 124, 95–102.
Neumann, M., & Naumann, M. (2007). Beyond IkappaBs: alternative regulation of NF-
kappaB activity. The FASEB Journal 21, 2642–2654.
Neviani, P., Harb, J. G., Oaks, J. J., Santhanam, R.,Walker, C. J., Ellis, J. J., ... Perrotti, D. (2013).
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic
stem cells. The Journal of Clinical Investigation 123, 4144–4157.
Neviani, P., Santhanam, R., Oaks, J. J., Eiring, A. M., Notari, M., Blaser, B. W., ... Perrotti, D.
(2007). FTY720, a new alternative for treating blast crisis chronic myelogenous
198 A.R. Clark, M. Ohlmeyer / Pharmacology & Therapeutics 201 (2019) 181–201leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. The
Journal of Clinical Investigation 117, 2408–2421.
Newman, R., McHugh, J., & Turner, M. (2016). RNA binding proteins as regulators of im-
mune cell biology. Clinical and Experimental Immunology 183, 37–49.
Ngoc, L. V., Wauquier, C., Soin, R., Bousbata, S., Twyffels, L., Kruys, V., & Gueydan, C. (2014).
Rapid proteasomal degradation of posttranscriptional regulators of the TIS11/
tristetraprolin family is induced by an intrinsically unstructured region indepen-
dently of ubiquitination. Molecular and Cellular Biology 34, 4315–4328.
Noda, H., Takeuchi, H., Mizuno, T., & Suzumura, A. (2013). Fingolimod phosphate pro-
motes the neuroprotective effects of microglia. Journal of Neuroimmunology 256,
13–18.
Nunbhakdi-Craig, V., Schuechner, S., Sontag, J. M., Montgomery, L., Pallas, D. C., Juno, C., ...
Sontag, E. (2007). Expression of protein phosphatase 2Amutants and silencing of the
regulatory B alpha subunit induce a selective loss of acetylated and detyrosinatedmi-
crotubules. Journal of Neurochemistry 101, 959–971.
Oaks, J., & Ogretmen, B. (2014). Regulation of PP2A by sphingolipid metabolism and sig-
naling. Frontiers in Oncology 4, 388.
Oaks, J. J., Santhanam, R., Walker, C. J., Roof, S., Harb, J. G., Ferenchak, G., ... Perrotti, D.
(2013). Antagonistic activities of the immunomodulator and PP2A-activating drug
FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 122,
1923–1934.
O'Connor, C. M., Perl, A., Leonard, D., Sangodkar, J., & Narla, G. (2017). Therapeutic
Targeting of PP2A. The International Journal of Biochemistry & Cell Biology 96, 182–193.
Ogris, E., Sontag, E., Wadzinski, B., & Narla, G. (2018). Speciﬁcity of research antibodies:
"trust is good, validation is better". Human Pathology 72, 199–201.
Omar, H. A., Chou, C. C., Berman-Booty, L. D., Ma, Y., Hung, J. H., Wang, D., ... Chen, C. S.
(2011). Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720,
in hepatocellular carcinoma. Hepatology 53, 1943–1958.
Omar, H. A., Tolba, M. F., Hung, J. H., & Al-Tel, T. H. (2016). OSU-2S/Sorafenib synergistic
antitumor combination against hepatocellular carcinoma: the role of PKCdelta/p53.
Frontiers in Pharmacology 7, 463.
O'Neil, J. D., Ammit, A. J., & Clark, A. R. (2018). MAPK p38 regulates inﬂammatory gene ex-
pression via tristetraprolin: doing good by stealth. The International Journal of
Biochemistry & Cell Biology 94, 6–9.
O'Neil, J. D., Ross, E. A., Ridley, M. L., Ding, Q., Tang, T., Rosner, D. R., ... Clark, A. R. (2017).
Gain-of-function mutation of tristetraprolin impairs negative feedback control of
macrophages in vitro, yet has overwhelmingly anti-inﬂammatory consequences
in vivo. Molecular and Cellular Biology 37, e00536-16.
O'Neill, L. A., Golenbock, D., & Bowie, A. G. (2013). The history of Toll-like receptors -
redeﬁning innate immunity. Nature Reviews. Immunology 13, 453–460.
Oo, M. L., Thangada, S., Wu, M. T., Liu, C. H., Macdonald, T. L., Lynch, K. R., ... Hla, T. (2007).
Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 ago-
nists induce ubiquitinylation and proteasomal degradation of the receptor. The
Journal of Biological Chemistry 282, 9082–9089.
Orihuela, R., McPherson, C. A., & Harry, G. J. (2016). Microglial M1/M2 polarization and
metabolic states. British Journal of Pharmacology 173, 649–665.
Ozaki, A., Morimoto, H., Tanaka, H., Okamura, H., Yoshida, K., Amorim, B. R., & Haneji, T.
(2006). Okadaic acid induces phosphorylation of p65NF-kappaB on serine 536 and
activates NF-kappaB transcriptional activity in human osteoblastic MG63 cells.
Journal of Cellular Biochemistry 99, 1275–1284.
Pang, J., Chen, Y., Kuai, L., Yang, P., Peng, J., Wu, Y., ... Jiang, Y. (2017). Inhibition of blood-
brain barrier disruption by an apolipoprotein e-mimetic peptide ameliorates early
brain injury in experimental subarachnoid hemorrhage. Translational Stroke
Research 8, 257–272.
Park, E. S., Choi, S., Shin, B., Yu, J., Yu, J., Hwang, J. M., ... Rho, J. (2015). Tumor necrosis fac-
tor (TNF) receptor-associated factor (TRAF)-interacting protein (TRIP) negatively
regulates the TRAF2 ubiquitin-dependent pathway by suppressing the TRAF2-
sphingosine 1-phosphate (S1P) interaction. The Journal of Biological Chemistry 290,
9660–9673.
Park, H. J., Lee, K. W., Park, E. S., Oh, S., Yan, R., Zhang, J., ... Mouradian, M. M. (2016). Dys-
regulation of protein phosphatase 2A in parkinson disease and dementia with lewy
bodies. Annals of Clinical Translational Neurology 3, 769–780.
Park, J. M., Lee, T. H., & Kang, T. H. (2018). Roles of tristetraprolin in tumorigenesis.
International Journal of Molecular Sciences 19.
Patel, B. S., Rahman, M. M., Rumzhum, N. N., Oliver, B. G., Verrills, N. M., & Ammit, A.
J. (2016). Theophylline represses IL-8 secretion from airway smooth muscle
cells independently of phosphodiesterase inhibition. Novel role as a protein
phosphatase 2A activator. American Journal of Respiratory Cell and Molecular Bi-
ology 54, 792–801.
Patmanathan, S. N., Yap, L. F., Murray, P. G., & Paterson, I. C. (2015). The antineoplastic
properties of FTY720: evidence for the repurposing of ﬁngolimod. Journal of Cellular
and Molecular Medicine 19, 2329–2340.
Pattison, M. J., Mitchell, O., Flynn, H. R., Chen, C. S., Yang, H. T., Ben-Addi, H., ... Ley, S. C.
(2016). TLR and TNF-R1 activation of the MKK3/MKK6-p38alpha axis in macro-
phages is mediated by TPL-2 kinase. The Biochemical Journal 473, 2845–2861.
Paugh, S. W., Payne, S. G., Barbour, S. E., Milstien, S., & Spiegel, S. (2003). The immunosup-
pressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Letters 554,
189–193.
Peng, D., Wang, Z., Huang, A., Zhao, Y., & Qin, F. X. (2017). A novel function of F-box pro-
tein FBXO17 in negative regulation of type I IFN signaling by recruiting PP2A for IFN
regulatory factor 3 deactivation. Journal of Immunology 198, 808–819.
Peng, S. L. (2008). Transcription factors in autoimmune diseases. Frontiers in Bioscience 13,
4218–4240.
Perrotti, D., & Neviani, P. (2006). ReSETting PP2A tumour suppressor activity in blast crisis
and imatinib-resistant chronic myelogenous leukaemia. British Journal of Cancer 95,
775–781.Perrotti, D., & Neviani, P. (2013). Protein phosphatase 2A: a target for anticancer therapy.
The Lancet Oncology 14, e229–e238.
Perryman, M. S., Tessier, J., Wiher, T., O'Donoghue, H., McCracken, A. N., Kim, S. M., ...
Hanessian, S. (2016). Effects of stereochemistry, saturation, and hydrocarbon chain
length on the ability of synthetic constrained azacyclic sphingolipids to trigger nutri-
ent transporter down-regulation, vacuolation, and cell death. Bioorganic & Medicinal
Chemistry 24, 4390–4397.
Pippa, R., Dominguez, A., Christensen, D. J., Moreno-Miralles, I., Blanco-Prieto, M. J., Vitek,
M. P., & Odero, M. D. (2014). Effect of FTY720 on the SET-PP2A complex in acute my-
eloid leukemia; SET binding drugs have antagonistic activity. Leukemia 28,
1915–1918.
Pitman, M. R., Woodcock, J. M., Lopez, A. F., & Pitson, S. M. (2012). Molecular targets of
FTY720 (ﬁngolimod). Current Molecular Medicine 12, 1207–1219.
Pullar, C. E., Chen, J., & Isseroff, R. R. (2003). PP2A activation by beta2-adrenergic receptor
agonists: novel regulatory mechanism of keratinocyte migration. The Journal of
Biological Chemistry 278, 22555–22562.
Pusey, M., Bail, S., Xu, Y., Buiakova, O., Nestor, M., Yang, J. J., & Rice, L. M. (2016). Inhibition
of protein methylesterase 1 decreased cancerous phenotypes in endometrial adeno-
carcinoma cell lines and xenograft tumor models. Tumour Biology 37, 11835–11842.
Qin, C., Fan,W. H., Liu, Q., Shang, K., Murugan,M.,Wu, L. J., ... Tian, D. S. (2017). Fingolimod
protects against ischemic white matter damage by modulating microglia toward M2
polarization via STAT3 pathway. Stroke 48, 3336–3346.
Qin, X., You, H., Cao, F., Wu, Y., Peng, J., Pang, J., ... Jiang, Y. (2017). Apolipoprotein e mi-
metic peptide increases cerebral glucose uptake by reducing blood-brain barrier dis-
ruption after controlled cortical impact in mice: an (18)F-ﬂuorodeoxyglucose PET/CT
study. Journal of Neurotrauma 34, 943–951.
Rahman, M. M., Prabhala, P., Rumzhum, N. N., Patel, B. S., Wickop, T., Hansbro, P. M., ...
Ammit, A. J. (2016). TLR2 ligation induces corticosteroid insensitivity in A549 lung
epithelial cells: anti-inﬂammatory impact of PP2A activators. The International
Journal of Biochemistry & Cell Biology 78, 279–287.
Rahman, M. M., Rumzhum, N. N., Hansbro, P. M., Morris, J. C., Clark, A. R., Verrills, N. M., &
Ammit, A. J. (2016). Activating protein phosphatase 2A (PP2A) enhances
tristetraprolin (TTP) anti-inﬂammatory function in A549 lung epithelial cells.
Cellular Signalling 28, 325–334.
Rahman, M. M., Rumzhum, N. N., Morris, J. C., Clark, A. R., Verrills, N. M., & Ammit, A. J.
(2015). Basal protein phosphatase 2A activity restrains cytokine expression: role
for MAPKs and tristetraprolin. Scientiﬁc Reports 5, 10063.
Raman, D., & Pervaiz, S. (2019). Redox inhibition of protein phosphatase PP2A: potential
implications in oncogenesis and its progression. Redox Biology, 101105. https://doi.
org/10.1016/j.redox.2019.101105.
Ramaswamy, K., Spitzer, B., & Kentsis, A. (2015). Therapeutic re-activation of protein
phosphatase 2A in acute myeloid leukemia. Frontiers in Oncology 5, 16.
Ranieri, A., Kemp, E., Burgoyne, J. R., & Avkiran, M. (2018). Beta-adrenergic regulation of
cardiac type 2A protein phosphatase through phosphorylation of regulatory subunit
B56delta at S573. Journal of Molecular and Cellular Cardiology 115, 20–31.
Reines, I., Kietzmann, M., Mischke, R., Tschernig, T., Luth, A., Kleuser, B., & Baumer, W.
(2009). Topical application of sphingosine-1-phosphate and FTY720 attenuate aller-
gic contact dermatitis reaction through inhibition of dendritic cell migration. The
Journal of Investigative Dermatology 129, 1954–1962.
Ren, M., Han, M., Wei, X., Guo, Y., Shi, H., Zhang, X., ... Lou, H. (2017). FTY720 attenuates 6-
OHDA-associated dopaminergic degeneration in cellular and mouse Parkinsonian
models. Neurochemical Research 42, 686–696.
Reynhout, S., & Janssens, V. (2019). Physiologic functions of PP2A: Lessons from geneti-
cally modiﬁed mice. Biochimica et Biophysica Acta, Molecular Cell Research 1866,
31–50.
Richard, N. P., Pippa, R., Cleary, M. M., Puri, A., Tibbitts, D., Mahmood, S., ... Agarwal, A.
(2016). Combined targeting of SET and tyrosine kinases provides an effective thera-
peutic approach in human T-cell acute lymphoblastic leukemia. Oncotarget 7,
84214–84227.
Rincon, R., Cristobal, I., Zazo, S., Arpi, O., Menendez, S., Manso, R., ... Rojo, F. (2015). PP2A
inhibition determines poor outcome and doxorubicin resistance in early breast can-
cer and its activation shows promising therapeutic effects. Oncotarget 6, 4299–4314.
Roberts, K. G., Smith, A. M., McDougall, F., Carpenter, H., Horan, M., Neviani, P., ... Verrills,
N. M. (2010). Essential requirement for PP2A inhibition by the oncogenic receptor c-
KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Research
70, 5438–5447.
Rolland,W. B., 2nd,Manaenko, A., Lekic, T., Hasegawa, Y., Ostrowski, R., Tang, J., & Zhang, J.
H. (2011). FTY720 is neuroprotective and improves functional outcomes after intra-
cerebral hemorrhage in mice. Acta Neurochirurgica. Supplement 111, 213–217.
Rolland, W. B., Lekic, T., Krafft, P. R., Hasegawa, Y., Altay, O., Hartman, R., ... Zhang, J. H.
(2013). Fingolimod reduces cerebral lymphocyte inﬁltration in experimental models
of rodent intracerebral hemorrhage. Experimental Neurology 241, 45–55.
Ross, C. R., Brennan-Laun, S. E., &Wilson, G. M. (2012). Tristetraprolin: roles in cancer and
senescence. Ageing Research Reviews 11, 473–484.
Ross, E. A., Naylor, A. J., O'Neil, J. D., Crowley, T., Ridley, M. L., Crowe, J., ... Clark, A. R.
(2017). Treatment of inﬂammatory arthritis via targeting of tristetraprolin, a master
regulator of pro-inﬂammatory gene expression. Annals of the Rheumatic Diseases,
612–619.
Ross, E. A., Smallie, T., Ding, Q., O'Neil, J. D., Cunliffe, H. E., Tang, T., ... Clark, A. R. (2015).
Dominant suppression of inﬂammation via targeted mutation of the mRNA
destabilizing protein tristetraprolin. Journal of Immunology 195, 265–276.
Rothhammer, V., Kenison, J. E., Tjon, E., Takenaka, M. C., de Lima, K. A., Borucki, D. M., ...
Quintana, F. J. (2017). Sphingosine 1-phosphate receptor modulation suppresses
pathogenic astrocyte activation and chronic progressive CNS inﬂammation.
Proceedings of the National Academy of Sciences of the United States of America 114,
2012–2017.
199A.R. Clark, M. Ohlmeyer / Pharmacology & Therapeutics 201 (2019) 181–201Rounbehler, R. J., Fallahi, M., Yang, C., Steeves, M. A., Li, W., Doherty, J. R., ... Cleveland, J. L.
(2012). Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant
state. Cell 150, 563–574.
Ruediger, R., Ruiz, J., & Walter, G. (2011). Human cancer-associated mutations in the
Aalpha subunit of protein phosphatase 2A increase lung cancer incidence in Aalpha
knock-in and knockout mice. Molecular and Cellular Biology 31, 3832–3844.
Ruger, K., Ottenlinger, F., Schroder, M., Zivkovic, A., Stark, H., Pfeilschifter, J. M., & Radeke,
H. H. (2014). Modulation of IL-33/ST2-TIR and TLR signalling pathway by ﬁngolimod
and analogues in immune cells. Scandinavian Journal of Immunology 80, 398–407.
Ruiz, A., Joshi, P., Mastrangelo, R., Francolini, M., Verderio, C., & Matteoli, M. (2014). Test-
ing Abeta toxicity on primary CNS cultures using drug-screening microﬂuidic chips.
Lab on a Chip 14, 2860–2866.
Ruvolo, P. P. (2015). The interplay between PP2A andmicroRNAs in leukemia. Frontiers in
Oncology 5, 43.
Ruvolo, P. P. (2016). The broken "Off" switch in cancer signaling: PP2A as a regulator of
tumorigenesis, drug resistance, and immune surveillance. BBA Clinical 6, 87–99.
Ruvolo, P. P., Deng, X., Ito, T., Carr, B. K., & May, W. S. (1999). Ceramide induces Bcl2 de-
phosphorylation via a mechanism involving mitochondrial PP2A. The Journal of
Biological Chemistry 274, 20296–20300.
Sabapathy, K. (2012). Role of the JNK pathway in human diseases. Progress in Molecular
Biology and Translational Science 106, 145–169.
Sabbagh, J. J., & Dickey, C. A. (2016). The metamorphic nature of the tau protein: dynamic
ﬂexibility comes at a cost. Frontiers in Neuroscience 10, 3.
Sablina, A. A., & Hahn, W. C. (2008). SV40 small T antigen and PP2A phosphatase in cell
transformation. Cancer Metastasis Reviews 27, 137–146.
Saddoughi, S. A., Gencer, S., Peterson, Y. K., Ward, K. E., Mukhopadhyay, A., Oaks, J., ...
Ogretmen, B. (2013). Sphingosine analogue drug FTY720 targets I2PP2A/SET andme-
diates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
EMBO Molecular Medicine 5, 105–121.
Saisho, Y. (2015). Metformin and inﬂammation: its potential beyond glucose-lowering ef-
fect. Endocrine, Metabolic & Immune Disorders Drug Targets 15, 196–205.
Sanchez, T., Skoura, A., Wu, M. T., Casserly, B., Harrington, E. O., & Hla, T. (2007). Induction
of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its
downstream effectors ROCK and PTEN. Arteriosclerosis, Thrombosis, and Vascular
Biology 27, 1312–1318.
Sandler, H., Kreth, J., Timmers, H. T., & Stoecklin, G. (2011). Not1 mediates recruitment of
the deadenylase Caf1 to mRNAs targeted for degradation by tristetraprolin. Nucleic
Acids Research 39, 4373–4386.
Sandler, H., & Stoecklin, G. (2008). Control of mRNA decay by phosphorylation of
tristetraprolin. Biochemical Society Transactions 36, 491–496.
Sanduja, S., Blanco, F. F., Young, L. E., Kaza, V., & Dixon, D. A. (2012). The role of
tristetraprolin in cancer and inﬂammation. Frontiers in Bioscience 17, 174–188.
Sangodkar, J., Perl, A., Tohme, R., Kiselar, J., Kastrinsky, D. B., Zaware, N., ... Narla, G. (2017).
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. The
Journal of Clinical Investigation 127, 2081–2090.
Schott, K., Fuchs, N. V., Derua, R., Mahboubi, B., Schnellbacher, E., Seifried, J., ... Konig, R.
(2018). Dephosphorylation of the HIV-1 restriction factor SAMHD1 is mediated by
PP2A-B55alpha holoenzymes during mitotic exit. Nature Communications 9, 2227.
Sedlyarov, V., Fallmann, J., Ebner, F., Huemer, J., Sneezum, L., Ivin, M., ... Kovarik, P. (2016).
Tristetraprolin binding site atlas in the macrophage transcriptome reveals a switch
for inﬂammation resolution. Molecular Systems Biology 12, 868.
Segura-Ulate, I., Belcher, T. K., Vidal-Martinez, G., Vargas-Medrano, J., & Perez, R. G.
(2017). FTY720-derivatives do not induce FTY720-like lymphopenia. Journal of
Pharmacological Sciences 133, 187–189.
Sents, W., Ivanova, E., Lambrecht, C., Haesen, D., & Janssens, V. (2013). The biogenesis of
active protein phosphatase 2A holoenzymes: a tightly regulated process creating
phosphatase speciﬁcity. The FEBS Journal 280, 644–661.
Sents, W., Meeusen, B., Kalev, P., Radaelli, E., Sagaert, X., Miermans, E., ... Janssens, V.
(2017). PP2A inactivation mediated by PPP2R4 haploinsufﬁciency promotes cancer
development. Cancer Research 77, 6825–6837.
del Ser, T., Steinwachs, K. C., Gertz, H. J., Andres, M. V., Gomez-Carrillo, B., Medina, M., ...
Leon, T. (2013). Treatment of Alzheimer's diseasewith the GSK-3 inhibitor tideglusib:
a pilot study. Journal of Alzheimer's Disease 33, 205–215.
Serdar, M., Herz, J., Kempe, K., Lumpe, K., Reinboth, B. S., Sizonenko, S. V., ... Bendix, I.
(2016). Fingolimod protects against neonatal white matter damage and long-term
cognitive deﬁcits caused by hyperoxia. Brain, Behavior, and Immunity 52, 106–119.
Shanley, T. P., Vasi, N., Denenberg, A., & Wong, H. R. (2001). The serine/threonine phos-
phatase, PP2A: endogenous regulator of inﬂammatory cell signaling. Journal of
Immunology 166, 966–972.
Shi, Q., Xiong, B., Zhong, J., Wang, H., Ma, D., & Miao, C. (2017). MFHAS1 suppresses TLR4
signaling pathway via induction of PP2A C subunit cytoplasm translocation and inhi-
bition of c-Jun dephosphorylation at Thr239. Molecular Immunology 88, 79–88.
Shimizu, Y., Taraborrelli, L., & Walczak, H. (2015). Linear ubiquitination in immunity.
Immunological Reviews 266, 190–207.
Shlomai, G., Zelenko, Z., Antoniou, I. M., Stasinopoulos, M., Tobin-Hess, A., Vitek, M. P., ...
Gallagher, E. J. (2017). OP449 inhibits breast cancer growth without adverse meta-
bolic effects. Endocrine-Related Cancer 24, 519–529.
Shu, G., Zhang, L., Jiang, S., Cheng, Z., Wang, G., Huang, X., & Yang, X. (2016). Isoliensinine
induces dephosphorylation of NF-kB p65 subunit at Ser536 via a PP2A-dependent
mechanism in hepatocellular carcinoma cells: roles of impairing PP2A/I2PP2A inter-
action. Oncotarget 7, 40285–40296.
Siehler, S., & Manning, D. R. (2002). Pathways of transduction engaged by sphingosine 1-
phosphate through G protein-coupled receptors. Biochimica et Biophysica Acta 1582,
94–99.
Skaper, S. D., Facci, L., Zusso, M., & Giusti, P. (2018). An inﬂammation-centric view of neu-
rological disease: beyond the neuron. Frontiers in Cellular Neuroscience 12, 72.Skoura, A., Michaud, J., Im, D. S., Thangada, S., Xiong, Y., Smith, J. D., & Hla, T. (2011).
Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular in-
ﬂammation and atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 31,
81–85.
Skoura, A., Sanchez, T., Claffey, K., Mandala, S. M., Proia, R. L., & Hla, T. (2007). Essential
role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the
mouse retina. The Journal of Clinical Investigation 117, 2506–2516.
Smallie, T., Ross, E. A., Ammit, A. J., Cunliffe, H. E., Tang, T., Rosner, D. R., ... Clark, A. R.
(2015). Dual-speciﬁcity phosphatase 1 and tristetraprolin cooperate to regulate mac-
rophage responses to lipopolysaccharide. Journal of Immunology 195, 277–288.
Smith, A. M., Dun, M. D., Lee, E. M., Harrison, C., Kahl, R., Flanagan, H., ... Verrills, N. M.
(2016). Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia
cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. Oncotarget 7,
47465–47478.
Sokulsky, L. A., Collison, A. M., Nightingale, S., Fevre, A. L., Percival, E., Starkey, M. R., ...
Mattes, J. (2016). TRAIL deﬁciency and PP2A activation with salmeterol ameliorates
egg allergen-driven eosinophilic esophagitis. American Journal of Physiology. Gastroin-
testinal and Liver Physiology 311, G998–G1008.
Sontag, E., Nunbhakdi-Craig, V., Lee, G., Bloom, G. S., & Mumby,M. C. (1996). Regulation of
the phosphorylation state and microtubule-binding activity of Tau by protein phos-
phatase 2A. Neuron 17, 1201–1207.
Sontag, E., Nunbhakdi-Craig, V., Lee, G., Brandt, R., Kamibayashi, C., Kuret, J., ... Bloom, G. S.
(1999). Molecular interactions among protein phosphatase 2A, tau, and microtu-
bules. Implications for the regulation of tau phosphorylation and the development
of tauopathies. The Journal of Biological Chemistry 274, 25490–25498.
Sontag, E., Sontag, J. M., & Garcia, A. (1997). Protein phosphatase 2A is a critical regulator
of protein kinase C zeta signaling targeted by SV40 small t to promote cell growth
and NF-kappaB activation. The EMBO Journal 16, 5662–5671.
Sontag, J. M., Nunbhakdi-Craig, V., & Sontag, E. (2013). Leucine carboxyl methyltransfer-
ase 1 (LCMT1)-dependent methylation regulates the association of protein phospha-
tase 2A and tau protein with plasma membrane microdomains in neuroblastoma
cells. The Journal of Biological Chemistry 288, 27396–27405.
Sontag, J. M., & Sontag, E. (2014). Protein phosphatase 2A dysfunction in Alzheimer's dis-
ease. Frontiers in Molecular Neuroscience 7, 16.
Sooﬁyani, S. R., Hejazi, M. S., & Baradaran, B. (2017). The role of CIP2A in cancer: a review
and update. Biomedicine & Pharmacotherapy 96, 626–633.
Spiegel, S., & Milstien, S. (2011). The outs and the ins of sphingosine-1-phosphate in im-
munity. Nature Reviews. Immunology 11, 403–415.
Stephenson, J., Nutma, E., van der Valk, P., & Amor, S. (2018). Inﬂammation in CNS neuro-
degenerative diseases. Immunology 154, 204–219.
Stoecklin, G., Stubbs, T., Kedersha, N., Wax, S., Rigby, W. F., Blackwell, T. K., & Anderson, P.
(2004). MK2-induced tristetraprolin:14-3-3 complexes prevent stress granule associ-
ation and ARE-mRNA decay. The EMBO Journal 23, 1313–1324.
Strub, G. M., Maceyka, M., Hait, N. C., Milstien, S., & Spiegel, S. (2010). Extracellular and
intracellular actions of sphingosine-1-phosphate. Advances in Experimental Medicine
and Biology 688, 141–155.
Sucksdorff, M., Rissanen, E., Tuisku, J., Nuutinen, S., Paavilainen, T., Rokka, J., ... Airas, L.
(2017). Evaluation of the effect of ﬁngolimod treatment on microglial activation
using serial PET imaging in multiple sclerosis. Journal of Nuclear Medicine 58,
1646–1651.
Sun, L., Pham, T. T., Cornell, T. T., McDonough, K. L., McHugh,W. M., Blatt, N. B., ... Shanley,
T. P. (2017). Myeloid-speciﬁc gene deletion of protein phosphatase 2A magniﬁes
MyD88- and TRIF-dependent inﬂammation following endotoxin challenge. Journal
of Immunology 198, 404–416.
Sun, L., Stoecklin, G., Van Way, S., Hinkovska-Galcheva, V., Guo, R. F., Anderson, P., &
Shanley, T. P. (2007). Tristetraprolin (TTP)-14-3-3 complex formation protects TTP
from dephosphorylation by protein phosphatase 2a and stabilizes tumor necrosis
factor-alpha mRNA. The Journal of Biological Chemistry 282, 3766–3777.
Sun, N., Shen, Y., Han, W., Shi, K., Wood, K., Fu, Y., ... Shi, F. D. (2016). Selective
sphingosine-1-phosphate receptor 1 modulation attenuates experimental intracere-
bral hemorrhage. Stroke 47, 1899–1906.
Sung, S. J., Walters, J. A., & Fu, S. M. (1992). Stimulation of tumor necrosis factor alpha pro-
duction in human monocytes by inhibitors of protein phosphatase 1 and 2A. The
Journal of Experimental Medicine 176, 897–901.
Suswam, E. A., Shacka, J. J., Walker, K., Lu, L., Li, X., Si, Y., ... King, P. H. (2013). Mutant
tristetraprolin: a potent inhibitor of malignant glioma cell growth. Journal of Neuro-
Oncology 113, 195–205.
Swingle, M., Ni, L., & Honkanen, R. E. (2007). Small-molecule inhibitors of ser/thr protein
phosphatases: speciﬁcity, use and common forms of abuse. Methods in Molecular
Biology 365, 23–38.
Switzer, C. H., Cheng, R. Y., Vitek, T. M., Christensen, D. J., Wink, D. A., & Vitek, M. P. (2011).
Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer
therapy. Oncogene 30, 2504–2513.
Sykes, D. A., Riddy, D. M., Stamp, C., Bradley, M. E., McGuiness, N., Sattikar, A., ... Charlton,
S. J. (2014). Investigating themolecular mechanisms through which FTY720-P causes
persistent S1P1 receptor internalization. British Journal of Pharmacology 171,
4797–4807.
Szymiczek, A., Pastorino, S., Larson, D., Tanji, M., Pellegrini, L., Xue, J., ... Yang, H. (2017).
FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model.
Journal of Translational Medicine 15, 58.
Taleski, G., & Sontag, E. (2018). Protein phosphatase 2A and tau: an orchestrated 'Pas de
Deux'. FEBS Letters 592, 1079–1095.
Tan, P. L., Shavlakadze, T., Grounds, M. D., & Arthur, P. G. (2015). Differential thiol oxida-
tion of the signaling proteins Akt, PTEN or PP2A determines whether Akt phosphor-
ylation is enhanced or inhibited by oxidative stress in C2C12 myotubes derived from
skeletal muscle. The International Journal of Biochemistry & Cell Biology 62, 72–79.
200 A.R. Clark, M. Ohlmeyer / Pharmacology & Therapeutics 201 (2019) 181–201Tanaka, H., Yoshida, K., Okamura, H., Morimoto, H., Nagata, T., & Haneji, T. (2007).
Calyculin A induces apoptosis and stimulates phosphorylation of p65NF-kappaB in
human osteoblastic osteosarcoma MG63 cells. International Journal of Oncology 31,
389–396.
Tang, T. J., Scambler, T. E., Smallie, T., Cunliffe, H. E., Ross, E. A., Rosner, D. R., ... Clark, A. R.
(2017). Macrophage responses to lipopolysaccharide are modulated by a feedback
loop involving prostaglandin E2, dual speciﬁcity phosphatase 1 and tristetraprolin.
Scientiﬁc Reports 7, 4350 in press.
Taniguchi, K., & Karin, M. (2018). NF-kappaB, inﬂammation, immunity and cancer: com-
ing of age. Nature Reviews. Immunology 18, 309–324.
Taylor, G. A., Carballo, E., Lee, D. M., Lai,W. S., Thompson, M. J., Patel, D. D., ... Blackshear, P.
J. (1996). A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and
autoimmunity resulting from tristetraprolin (TTP) deﬁciency. Immunity 4, 445–454.
Taymans, J. M., & Baekelandt, V. (2014). Phosphatases of alpha-synuclein, LRRK2, and tau:
important players in the phosphorylation-dependent pathology of Parkinsonism.
Frontiers in Genetics 5, 382.
Thevenin, C., Kim, S. J., Rieckmann, P., Fujiki, H., Norcross, M. A., Sporn, M. B., ... Kehrl, J. H.
(1990). Induction of nuclear factor-kappa B and the human immunodeﬁciency virus
long terminal repeat by okadaic acid, a speciﬁc inhibitor of phosphatases 1 and 2A.
The New Biologist 2, 793–800.
Thomas, K., Sehr, T., Proschmann, U., Rodriguez-Leal, F. A., Haase, R., & Ziemssen, T.
(2017). Fingolimod additionally acts as immunomodulator focused on the innate im-
mune system beyond its prominent effects on lymphocyte recirculation. Journal of
Neuroinﬂammation 14, 41.
Tibaldi, E., Pagano, M. A., Frezzato, F., Trimarco, V., Facco, M., Zagotto, G., ... Trentin, L.
(2017). Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of
chronic lymphocytic leukemia cells. Haematologica 102, 1401–1412.
Tiedje, C., Diaz-Munoz, M. D., Trulley, P., Ahlfors, H., Laass, K., Blackshear, P. J., ... Gaestel,
M. (2016). The RNA-binding protein TTP is a global post-transcriptional regulator
of feedback control in inﬂammation. Nucleic Acids Research 44, 7418–7440.
Tohme, R., Izadmehr, S., Gandhe, S., Tabaro, G., Vallabhaneni, S., Thomas, A., ... Narla, G.
(2019). Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-
resistant lung adenocarcinoma. JCI Insight 4.
Toop, H. D., Dun, M. D., Ross, B. K., Flanagan, H. M., Verrills, N. M., & Morris, J. C. (2016).
Development of novel PP2A activators for use in the treatment of acute myeloid leu-
kaemia. Organic & Biomolecular Chemistry 14, 4605–4616.
Tran, D. D., Koch, A., Allister, A., Saran, S., Ewald, F., Koch, M., ... Tamura, T. (2016). Treat-
ment with MAPKAP2 (MK2) inhibitor and DNA methylation inhibitor, 5-aza dC, syn-
ergistically triggers apoptosis in hepatocellular carcinoma (HCC) via tristetraprolin
(TTP). Cellular Signalling 28, 1872–1880.
Tran, H. T., Nimick, M., Uhrig, R. G., Templeton, G., Morrice, N., Gourlay, R., ... Moorhead, G.
B. (2012). Arabidopsis thaliana histone deacetylase 14 (HDA14) is an alpha-tubulin
deacetylase that associates with PP2A and enriches in the microtubule fraction
with the putative histone acetyltransferase ELP3. The Plant Journal 71, 263–272.
Tsuchiya, Y., Osaki, K., Kanamoto, M., Nakao, Y., Takahashi, E., Higuchi, T., & Kamata, H.
(2017). Distinct B subunits of PP2A regulate the NF-kappaB signalling pathway
through dephosphorylation of IKKbeta, IkappaBalpha and RelA. FEBS Letters 591,
4083–4094.
Tukhovskaya, E. A., Yukin, A. Y., Khokhlova, O. N., Murashev, A. N., & Vitek, M. P. (2009).
COG1410, a novel apolipoprotein-E mimetic, improves functional and morphological
recovery in a rat model of focal brain ischemia. Journal of Neuroscience Research 87,
677–682.
Turner, N., Lim, X. Y., Toop, H. D., Osborne, B., Brandon, A. E., Taylor, E. N., ... Don, A. S.
(2018). A selective inhibitor of ceramide synthase 1 reveals a novel role in fat metab-
olism. Nature Communications 9, 3165.
Vargas-Medrano, J., Krishnamachari, S., Villanueva, E., Godfrey, W. H., Lou, H.,
Chinnasamy, R., ... Perez, R. G. (2014). Novel FTY720-based compounds stimulate
neurotrophin expression and phosphatase activity in dopaminergic cells. ACS
Medicinal Chemistry Letters 5, 782–786.
Velmurugan, B. K., Lee, C. H., Chiang, S. L., Hua, C. H., Chen, M. C., Lin, S. H., ... Ko, Y. C.
(2018). PP2A deactivation is a common event in oral cancer and reactivation by
FTY720 shows promising therapeutic potential. Journal of Cellular Physiology 233,
1300–1311.
Vidal-Martinez, G., Vargas-Medrano, J., Gil-Tommee, C., Medina, D., Garza, N. T.,
Yang, B., ... Perez, R. G. (2016). FTY720/ﬁngolimod reduces synucleinopathy
and improves gut motility in A53T mice: contributions of pro-brain-derived neu-
rotrophic factor (Pro-BDNF) and mature BDNF. The Journal of Biological Chemistry
291, 20811–20821.
Voronkov, M., Braithwaite, S. P., & Stock, J. B. (2011). Phosphoprotein phosphatase 2A: a
novel druggable target for Alzheimer's disease. Future Medicinal Chemistry 3,
821–833.
Wagner, E. F. (2010). Bone development and inﬂammatory disease is regulated by AP-1
(Fos/Jun). Annals of the Rheumatic Diseases 69(Suppl. 1), i86–i88.
Wallington-Beddoe, C. T., Don, A. S., Hewson, J., Qiao, Q., Papa, R. A., Lock, R. B., ... Bendall,
L. J. (2012). Disparate in vivo efﬁcacy of FTY720 in xenograft models of Philadelphia
positive and negative B-lineage acute lymphoblastic leukemia. PLoS One 7, e36429.
Wallington-Beddoe, C. T., Hewson, J., Bradstock, K. F., & Bendall, L. J. (2011). FTY720 pro-
duces caspase-independent cell death of acute lymphoblastic leukemia cells.
Autophagy 7, 707–715.
Wang, H., Xu, K., Wang, B., Liu, J., Wang, X., Xing, M., ... Xu, L. (2017). Microcystin-LR in-
duces a wide variety of biochemical changes in the A549 human non-small cell
lung cancer cell line: roles for protein phosphatase 2A and its substrates.
Environmental Toxicology 32, 1065–1078.
Wang, J., Okkeri, J., Pavic, K., Wang, Z., Kauko, O., Halonen, T., ... Westermarck, J. (2017).
Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56.
EMBO Reports 18, 437–450.Wang, X., Blanchard, J., Tung, Y. C., Grundke-Iqbal, I., & Iqbal, K. (2015). Inhibition of pro-
tein phosphatase-2A (PP2A) by I1PP2A Leads to hyperphosphorylation of tau, neuro-
degeneration, and cognitive impairment in rats. Journal of Alzheimer's Disease 45,
423–435.
Wang, Z., Yang, H., Tachado, S. D., Capo-Aponte, J. E., Bildin, V. N., Koziel, H., & Reinach, P. S.
(2006). Phosphatase-mediated crosstalk control of ERK and p38 MAPK signaling in
corneal epithelial cells. Investigative Ophthalmology & Visual Science 47, 5267–5275.
Ward, M. D., Jones, D. E., & Goldman, M. D. (2014). Overview and safety of ﬁngolimod hy-
drochloride use in patients with multiple sclerosis. Expert Opinion on Drug Safety 13,
989–998.
Ward, S. M., Himmelstein, D. S., Lancia, J. K., & Binder, L. I. (2012). Tau oligomers and tau
toxicity in neurodegenerative disease. Biochemical Society Transactions 40, 667–671.
Wei, Y., Yemisci, M., Kim, H. H., Yung, L. M., Shin, H. K., Hwang, S. K., ... Waeber, C. (2011).
Fingolimod provides long-term protection in rodent models of cerebral ischemia.
Annals of Neurology 69, 119–129.
Westermarck, J., & Hahn, W. C. (2008). Multiple pathways regulated by the tumor sup-
pressor PP2A in transformation. Trends in Molecular Medicine 14, 152–160.
Westermarck, J., Holmstrom, T., Ahonen, M., Eriksson, J. E., & Kahari, V. M. (1998). En-
hancement of ﬁbroblast collagenase-1 (MMP-1) gene expression by tumor promoter
okadaic acid is mediated by stress-activated protein kinases Jun N-terminal kinase
and p38. Matrix Biology 17, 547–557.
Westermarck, J., Li, S. P., Kallunki, T., Han, J., & Kahari, V. M. (2001). p38mitogen-activated
protein kinase-dependent activation of protein phosphatases 1 and 2A inhibits MEK1
and MEK2 activity and collagenase 1 (MMP-1) gene expression. Molecular and
Cellular Biology 21, 2373–2383.
Wilker, E., & Yaffe, M. B. (2004). 14-3-3 Proteins–a focus on cancer and human disease.
Journal of Molecular and Cellular Cardiology 37, 633–642.
Wiredja, D. D., Ayati, M., Mazhar, S., Sangodkar, J., Maxwell, S., Schlatzer, D., ... Chance, M.
R. (2017). Phosphoproteomics proﬁling of nonsmall cell lung cancer cells treated
with a novel phosphatase activator. Proteomics 17.
Witt, J., Barisic, S., Schumann, E., Allgower, F., Sawodny, O., Sauter, T., & Kulms, D. (2009).
Mechanism of PP2A-mediated IKK beta dephosphorylation: a systems biological ap-
proach. BMC Systems Biology 3, 71.
Wu, J., Lou, H., Alerte, T. N., Stachowski, E. K., Chen, J., Singleton, A. B., ... Perez, R. G. (2012).
Lewy-like aggregation of alpha-synuclein reduces protein phosphatase 2A activity
in vitro and in vivo. Neuroscience 207, 288–297.
Wu, Y., Pang, J., Peng, J., Cao, F., Vitek, M. P., Li, F., ... Sun, X. (2016). An apoE-derivedmimic
peptide, COG1410, alleviates early brain injury via reducing apoptosis and neuroin-
ﬂammation in a mouse model of subarachnoid hemorrhage. Neuroscience Letters
627, 92–99.
Xu, L., He, D., & Bai, Y. (2016). Microglia-mediated inﬂammation and neurodegenerative
disease. Molecular Neurobiology 53, 6709–6715.
Xu, Y., Chen, Y., Zhang, P., Jeffrey, P. D., & Shi, Y. (2008). Structure of a protein phosphatase
2A holoenzyme: insights into B55-mediated tau dephosphorylation. Molecular Cell
31, 873–885.
Xu, Y., Xing, Y., Chen, Y., Chao, Y., Lin, Z., Fan, E., ... Shi, Y. (2006). Structure of the protein
phosphatase 2A holoenzyme. Cell 127, 1239–1251.
Yaffe, M. B. (2002). How do 14-3-3 proteinswork? – Gatekeeper phosphorylation and the
molecular anvil hypothesis. FEBS Letters 513, 53–57.
Yan, H., Yi, S., Zhuang, H., Wu, L., Wang, D.W., & Jiang, J. (2018). Sphingosine-1-phosphate
ameliorates the cardiac hypertrophic response through inhibiting the activity of his-
tone deacetylase-2. International Journal of Molecular Medicine 41, 1704–1714.
Yan, L., Lavin, V. A., Moser, L. R., Cui, Q., Kanies, C., & Yang, E. (2008). PP2A regulates the
pro-apoptotic activity of FOXO1. The Journal of Biological Chemistry 283, 7411–7420.
Yang, J., Fan, G. H., Wadzinski, B. E., Sakurai, H., & Richmond, A. (2001). Protein phospha-
tase 2A interacts with and directly dephosphorylates RelA. The Journal of Biological
Chemistry 276, 47828–47833.
Yang, Y., Huang, Q., Lu, Y., Li, X., & Huang, S. (2012). Reactivating PP2A by FTY720 as a
novel therapy for AML with C-KIT tyrosine kinase domain mutation. Journal of
Cellular Biochemistry 113, 1314–1322.
Yoza, B. K., Wells, J. D., & McCall, C. E. (1998). Interleukin-1beta expression after inhibition
of protein phosphatases in endotoxin-tolerant cells. Clinical and Diagnostic Laboratory
Immunology 5, 281–287.
Yu, U. Y., & Ahn, J. H. (2010). Phosphorylation on the PPP2R5D B regulatory subunit mod-
ulates the biochemical properties of protein phosphatase 2A. BMB Reports 43,
263–267.
Zemann, B., Kinzel, B., Muller, M., Reuschel, R., Mechtcheriakova, D., Urtz, N., ... Billich, A.
(2006). Sphingosine kinase type 2 is essential for lymphopenia induced by the immu-
nomodulatory drug FTY720. Blood 107, 1454–1458.
Zeng, X., Wang, T., Zhu, C., Xing, X., Ye, Y., Lai, X., ... Zeng, Y. (2012). Topographical and bi-
ological evidence revealed FTY720-mediated anergy-polarization of mouse bone
marrow-derived dendritic cells in vitro. PLoS One 7, e34830.
Zhang, G., Yang, L., Kim, G. S., Ryan, K., Lu, S., O'Donnell, R. K., ... Sanchez, T. (2013). Critical
role of sphingosine-1-phosphate receptor 2 (S1PR2) in acute vascular inﬂammation.
Blood 122, 443–455.
Zhang, H., Taylor, W. R., Joseph, G., Caracciolo, V., Gonzales, D. M., Sidell, N., ... Kallen, C. B.
(2013). mRNA-binding protein ZFP36 is expressed in atherosclerotic lesions and re-
duces inﬂammation in aortic endothelial cells. Arteriosclerosis, Thrombosis, and
Vascular Biology 33, 1212–1220.
Zhang, L., Lu, L., Zhong, X., Yue, Y., Hong, Y., Li, Y., & Li, Y. (2019). Metformin reduced
NLRP3 inﬂammasome activity in Ox-LDL stimulatedmacrophages through adenosine
monophosphate activated protein kinase and protein phosphatase 2A. European Jour-
nal of Pharmacology 852, 99–106.
Zhang, T., Park, K. A., Li, Y., Byun, H. S., Jeon, J., Lee, Y., ... Hur, G. M. (2013). PHF20 regulates
NF-kappaB signalling by disrupting recruitment of PP2A to p65. Nature
Communications 4, 2062.
201A.R. Clark, M. Ohlmeyer / Pharmacology & Therapeutics 201 (2019) 181–201Zhang, W., An, J., Jawadi, H., Siow, D. L., Lee, J. F., Zhao, J., ... Lee, M. J. (2013). Sphingosine-
1-phosphate receptor-2 mediated NFkappaB activation contributes to tumor necrosis
factor-alpha induced VCAM-1 and ICAM-1 expression in endothelial cells.
Prostaglandins & Other Lipid Mediators 106, 62–71.
Zhang, X. X., Fu, Z., Zhang, Z., Miao, C., Xu, P., Wang, T., ... Cheng, S. (2012). Microcystin-LR
promotes melanoma cell invasion and enhances matrix metalloproteinase-2/-9 ex-
pression mediated by NF-kappaB activation. Environmental Science & Technology 46,
11319–11326.
Zhao, B., Sun, L., Haas, M., Denenberg, A. G., Wong, H. R., & Shanley, T. P. (2008). PP2A reg-
ulates upstream members of the c-jun N-terminal kinase mitogen-activated protein
kinase signaling pathway. Shock 29, 181–188.Zhao, P., Yang, X., Yang, L., Li, M., Wood, K., Liu, Q., & Zhu, X. (2017). Neuroprotective ef-
fects of ﬁngolimod in mouse models of Parkinson's disease. The FASEB Journal 31,
172–179.
Zonta, F., Pagano, M. A., Trentin, L., Tibaldi, E., Frezzato, F., Trimarco, V., ... Brunati, A. M.
(2015). Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by
strengthening SET-mediated inhibition of PP2A. Blood 125, 3747–3755.
Zuhl, A. M., Mohr, J. T., Bachovchin, D. A., Niessen, S., Hsu, K. L., Berlin, J. M., ... Cravatt, B. F.
(2012). Competitive activity-based protein proﬁling identiﬁes aza-beta-lactams as a
versatile chemotype for serine hydrolase inhibition. Journal of the American Chemical
Society 134, 5068–5071.
